Author Index

Abe K, *see* Tsunoda, 253
Adnams C, *see* Meyer, 909
Afschrift M, *see* Voet, 169
Ambrosio G. Letter in regards to referee awards, 935
Amery A, *see* Birkenhäger, 735
Anderson RH, Becker AE. The heart: structure in health and disease, 288
Arcavi L, Benowitz NL. Clinical significance of genetic influences on cardiovascular drug metabolism, 311
Arima S, *see* Tsunoda, 253
Arita M, *see* Sato, 575
Asayama J, *see* Inoue, 373
Aupetit J-F, Timour Q, Larbre J-P, Loufoua-Moundanga J, Kioueh I, Lopez M, Faucon G. Arrhythmogenicity of antiarrhythmic drugs and intraventricular conduction disorders: possible aggravation by myocardial ischemia—study in the porcine in situ heart, 217
Aureli T, *see* Corsico, 241

Barbier F, *see* Voet, 169
Bassett AL, *see* Ten Eick, 611
Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension, 63
Baxter GF, Yellon DM. Attenuation of reperfusion-induced ventricular fibrillation in the rat isolated hypertrophied heart by preischemic diltiazem treatment, 225
Becker AE, *see* Anderson, 288
Becker RC. Thrombolytic agents and anticoagulants, 825
Behar S, *see* Mandelzweig, 117
Belcher PR, Drake-Holland AJ, Hynd JW, Noble MIM. Effects of trimetazidine on in vivo coronary arterial platelet thrombosis, 149
Bennett PB, Po S, Snyders DJ, Tamkun MM. Molecular and functional diversity of cloned cardiac potassium channels, 585
Benowitz NL, *see* Arcavi, 311
Bezstarosti K, *see* Koning, 801
Birkenhäger WH, Amery A. Hypertension is a real disease (reply to Mitchell letter in this issue), 735
Birkenhäger WH. Hypertensive labeling: does it have therapeutic impiications, 207
Birkenhäger WH. Hypertensive labeling (reply to Lund-Johansen letter in this issue), 729
Bokor D, *see* Di Somma, 119
Bolognesi R, *see* Zeppellini, 325
Bonnier JJRM, *see* de Jong, 677
Bøtker HE, Jensen HK, Krusell LR, Sørensen EV. Renal effects of xamoterol in patients with moderate heart failure, 111
Bouhaddioni N, *see* El Alaoui-Talibi, 357
Branzi A, *see* Galie, 337
Brater DC, Rudy DR, Voelker JR, Greene PK, Gehr T, Sica DA. Pharmacokinetics and pharmacodynamics of torasemide in patients with chronic renal insufficiency—preliminary evaluation, 69
Brayden JE, *see* Nelson, 605
Bril A, Landais L, Gout B. Actions and interactions of E-4031 and tedisamil on reperfusion-induced arrhythmias and QT interval in rat in vivo, 233

Caldarera I, *see* Galie, 337
Camm AJ, *see* Malcolm, 139
Candito M, *see* Gibelin, 333
Capello C, *see* Tubaro, 809
Carloni V, *see* Gentilini, 81
Carmeliet E. Use-dependent block of the delayed K^+ current in rabbit ventricular myocytes, 599
Carotenuto A, *see* Di Somma, 119
Chapman ID, *see* Cook, 555
Chatterjee K, Cheitlin M, Karliner J, Parmley W, Rapaport E, Scheinman M. Cardiology: an illustrated text/reference, 383
Cheitlin M, *see* Chatterjee, 383
Chen C-C, *see* Chen, 133
Chen M-F, Chen C-C, Chen W-J, Wu C-C, Liau C-S, Lee Y-T. Dose titration study of isradipine in Chinese patients with mild to moderate essential hypertension, 133
Chen W-J, *see* Chen, 133
Ciampricotti R, *see* de Jong, 677
Coetzee A, *see* Hattingh, 851
Cohen JD, *see* Lakatta, 643
Cohn JN. ACE inhibitors, 379
Cole WC. ATP-sensitive K^+ channels in cardiac ischemia: an endogenous mechanism for protection of the heart, 527
Colli S, *see* Sirtori, 817
Commerford P, *see* Meyer, 909
Conti F, *see* Corsico, 241
Cook NS, Chapman ID. Therapeutic potential of potassium channel openers in peripheral vascular disease and asthma, 555
Corday E, *see* Kobayashi, 159
Corsico N, Nardone A, Lucreziotti MR, Spagnoli LG, Pesce D, Aureli T, Di Cocco ME, Miccheli A, Conti F, Martelli E Arrigoni. Effect of propionyl-L-carnitine in a rat model of peripheral arteriopathy: a functional, histologic, and NMR spectroscopic study, 241
Coudray C, *see* Pucheu, 701
Cruickshank JM. Phosphodiesterase III inhibitors: long-term risks and short-term benefits, 655
Cucchini F, *see* Zepellini, 325

Dadoun-Dybal M, *see* Gibelin, 333
De Buyzere M, *see* Voet, 169
Decroly P, *see* Wright, 929
de Divitiis M, *see* Di Somma, 119
de Divitiis O, *see* Di Somma, 119
DeDomenico R, *see* Zeppellini, 325
de Jong JW, Bonnier JJRM, Huizer T, Ciampricotti R, Roelandt JRTC. Absence of beneficial effect of intravenous metoprolol given during angioplasty in patients with single-vessels coronary artery disease, 677
de Leiris J, *see* Pucheu, 701
De Luca N, Savonitto S, Ricciardelli B, Marchegiano R, Lamenza F, Lembo G, Trimarco B. Effects of the single and repeated administration of benzepril on systemic and forearm circulation and cardiac function in hypertensive patients, 211
de Vaal JB, *see* Patel, 97
Di Cocco ME, *see* Corsico, 241
Die Cas L, Metra M, Ferrari R, Visioli O. Acute and chronic effects of the dihydropyridine calcium antagonist nisoldipine on the resting and exercise hemodynamics, neurohumoral parameters and functional capacity of the patients with chronic heart failure, 103
Dietz R, *see* Osterziel, 881
Dinsmore R, *see* Texter, 273
Di Somma S, Liguori V, Petitto M, Carotenuto A, Bokor D, de Divitiis O, de Divitiis M. A double blind comparison of nicorandil and metoprolol in stable effort angina pectoris, 119
Drake-Holland AJ, *see* Belcher, 149
Duchatelle-Gourdon I, *see* Hartzell, 547
Dupont AG. The place of diuretics in the treatment of hypertension: a historical review of classical experience over 30 years, 55

Dupont AG, *see* Vercruysse, 721
Duprez D, *see* Voet, 169

Edvinsson L, *see* Leppert, 901
Egashira K, *see* Takahashi, 265
El Alaoui-Talibi Z, Bouhaddioni N, Morave J. Assessment of the cardiostimulant action of propionyl-L-carnitine on chronically volume-overloaded rat hearts, 357

Facchin D, *see* Proclemer, 683
Fan Z, *see* Hiraoko, 593
Faucon G, *see* Aupetit, 217
Favier A, *see* Pucheu, 701
Ferrari R, *see* Die Cas, 103
Feruglio GA, *see* Proclemer, 683
Findlay I. Effects of glibenclamide upon ATP-sensitive K-channels during metabolic inhibition of isolated rat cardiac myocytes, 495
Fitzgerald JD. Do partial agonist beta blockers have improved clinical utility?, 303
Fleg JL, *see* Lakatta, 643
Foschi M, *see* Gentilini, 81
Franceschini G, Paoletti R. Pharmacological control of hypertriglyceridema, 297
Freeman LC, Kass RS. Delayed rectifier potassium channels in ventricle and sinoatrial node of the guinea pig: molecular and regulatory properties, 627
Frohlich ED, *see* Lakatta, 643
Fujiwara R, Hayashi T, Kutsumi Y, Oida K, Tamai T, Nakai T, Miyabo S. Effects of nicorandil on cell proliferation and cholesteryl ester accumulation in arterial smooth muscle cells in culture, 365
Fukai K, *see* Orita, 713
Fukai T, *see* Takahaski, 265
Fukasawa M, *see* Orita, 713
Furukawa T, *see* Hiraoka, 593

Galie N, Branzi A, Magnani G, Melandri G, Caldarera I, Rapezzi C, Grattoni C, Magnani B. Effect of enoximone alone and in combination with metoprolol on myocardial function and energetics in severe congestive heart failure: improvement in hemodynamic and metabolic profile, 337
Garratt CJ, *see* Malcolm, 139
Gehr T, *see* Brater, 69
Gentilini P, Laffi G, LaVilla G, Carloni V, Foschi M, Romanelli RG, Marra F. Torasemide in the treatment of patients with cirrhosis and ascites, 81
Gerardi P, *see* Tubaro, 817
Gheorghiade M, *see* Sabbah, 349
Gibelin P, Dadoun-Dybal M, Candito M, Robillon JF, Morand P. Hemodynamic effects of prolonged enoximone infusion (7 days) in patients with severe chronic heart failure, 333
Glebisch G, Klein-Robbenhaar G, Klein-Robbenhaar J, Ratheiser K, Unwin R. Renal and extrarenal sites of action of diuretics, 11
Goldbourt U, *see* Mandelzweig, 117
Goldstein S, *see* Sabbah, 349
Gotto, Jr. AM, *see* Rossouw, 789
Gout B, *see* Bril, 233
Gradman AH, *see* Lakatta, 643
Grattoni C, *see* Galie, 337
Greene PK, *see* Brater, 69
Grover SA. Modifying serum lipids to prevent coronary heart disease: do we have a consensus?, 761

Haendchen RV, *see* Kobayashi, 159
Hagino T, *see* Tsunoda, 253
Hampton JR. Postinfarct heart failure: role of diuretic therapy, 863
Hansen J Fischer. Verapamil prevents sudden death in patients with increased heart size after an acute myocardial infarction, 381
Hansen JF, *see* Larsen, 915
Hartzell HC, Duchatelle-Goudon I. Regulation of the cardiac delayed rectifier K current by neurotransmitters and magnesium, 547
Harley A. The management of heart failure: a matter of definition?, 661
Harvey RD, *see* Ten Eick, 611
Hata H, *see* Takahashi, 265
Hattingh P, Coetzee A, Lochner A. Effects of beta-blockers and Ca^{2+} antagonists on the response of the isolated working rat heart to adrenergic stimulants after cardioplegic arrest, 851
Haugland H, *see* Omvik P, 125
Hayashi T, *see* Fujiwara, 365
Hedner T, *see* Leppert, 901
Hiraoka M, Fan Z, Furukawa T, Nakayama K, Sawanobori T. Activation and reactivation of the ATP-sensitive K^+ channel of the heart can be modified by drugs, 593
Hirooka S, *see* Orita, 713
Holm-Nielsen P, *see* Schmidt, 175
Huizer T, *see* de Jong, 677
Hynd JW, *see* Belcher, 149

Iisalo E, *see* Kaila, 839
Imai Y, *see* Tsunoda, 253
Inomata T, *see* Watanabe, 923
Inoue D, Shirayama T, Omori I, Inoue M, Sakei R, Ishibashi K, Miyazaki H, Yamahara Y, Tatsumi T, Asayama J, Nakagawa M. Electrophysiological effects of flecainide acetate on stretched guinea pig left atrial muscle fibers, 373
Inoue M, *see* Kanda, 795
Ishibashi K, *see* Inoue, 373
Iwasaki H, *see* Saso, 257
Izumi T, *see* Watanabe, 923

Javernaro A, *see* Zeppellini, 325
Jennings RB (ed), *see* Yellon, 185
Jensen HK, *see* Bøtker, 111

Kaila T, Iisalo E, Lehtonen A, Saarimaa H. The extent of $beta_1$- and $beta_2$-receptor occupancy in plasma assesses the antagonist activity of metoprolol, pindolol and propranolol in the elderly, 839
Kaplinsky E, *see* Mandelsweig, 117
Kamouchi M, *see* Kitamura, 539
Kanda T, Inoue M, Suzuki T, Murata K. Low-dose combination therapy with metoprolol and captopril for congestive heart failure in mice, 795
Karliner J, *see* Chatterjee, 383
Kass RS, *see* Freeman, 627
Kasuya H, *see* Takahashi, 265
Katoh H, *see* Ogawa, 621
Katz AM. Physiology of the heart, 2nd ed., 287
Kharkevitch T, *see* Wright, 929
Kindler J. Torasemide in advanced renal failure, 75
Kioueh I, *see* Aupetit, 217
Kitamura K., Kamouchi M. K channel openers activate different K channels in vascular smooth muscle cells, 539
Kiyosue T, *see* Sato, 575
Kjeldsen K, *see* Schmidt, 175
Klein-Robbenhaar G, *see* Giebisch, 11
Klein-Robbenhaar J, *see* Giebisch, 11
Kobayashi S, Tadokoro H, Ryden L, Sjoquist P-O, Haendchen RV, Corday E. Local beta-adrenergic blockade does not reduce infarct size after coronary occlusion and reperfusion: a study of coronary venous retroinfusion of metoprolol, 159
Kohi M, *see* Orita, 713
Koning MMG, Krams R, Xiao CS, van Meegen JR, Bezstarosti K, Lamers JMJ, Verdouw PD. Intracoronary trimetazidine does not improve recovery of regional function in a porcine model of repeated ischemia, 801
Kono T, *see* Sabbah, 349
Koyama S, *see* Watanabe, 923
Krams R, *see* Koning, 801
Krusell LR, *see* Bøtker, 111
Kuga T, *see* Takahashi, 265
Kutsumi Y, *see* Fujiwara, 365

Laffi G, *see* Gentilini, 81
Lakatta EG, Cohen JD, Fleg JL, Frohlich ED, Gradman AH. Hypertension in the elderly: age- and dis-

ease-related complications and therapeutic implications, 643
Lamenza F, *see* De Luca, 211
Lamers JMJ, *see* Koning, 801
Landais L, *see* Bril, 233
Larbre JP, *see* Aupetit, 217
Larsen CT, Sørum C, Rasmussen V, Hansen JF. Anipamil prevents ST depression in patients with stable angina pectoris, 915
La Villa G, *see* Gentilini, 81
Leary WP, *see* Reyes, 23
Leary WP, *see* Reyes, 29
Lee, Y-T, *see* Chen, 133
Lees R, *see* Texter, 273
Lehtonen A, *see* Kaila, 839
Lembo G, *see* De Luca, 211
Leppert J, Nilsson H, Myrdal U, Edvinsson L, Hedner T, Ringqvist I. Sympathetic activation after two weeks of nifedipine treatment in primary Raynaud's patients and controls, 901
Levine TB, *see* Sabbah, 349
Liau C-S, *see* Chen, 133
Liau Y-T, *see* Chen, 133
Libardoni M, *see* Zeppellini, 325
Liguori V, *see* Di Somma, 119
Lochner A, *see* Hattingh, 851
Locke TJ, *see* Sherry, 671
Lonfoua-Moundanga ., *see* Aupetit, 217
Lopez M, *see* Aupetit, 217
Lowenthal DT (ed). Geriatric cardiology, 383
Lucreziotti MR, *see* Corsico, 241
Lund-Johansen P, *see* Omvik, 125
Lund-Johansen P, *see* Omvik, 193
Lund-Johansen P. Hypertensive labeling (reply to Birkenhäger editorial in CDT 7:2), 727

Magnani B, *see* Galie, 337
Magnani G, *see* Galie, 337
Malcolm AD, Garratt CJ, Camm AJ. The therapeutic and diagnostic cardiac electrophysiological uses of adenosine, 139
Mancini M, Rubba P. Treating mild hypercholesterolemia in the absence of overt cardiovascular disease. If, when, why?. 775
Mancini M, *see* Rubba, 767
Mandelzweig L, Goldbourt U, Reicher-Reiss H, Behar S, Kaplinsky E. Nifedipine does not improve survival in AMI patients without heart failure, 117
Marchegiano R, *see* De Luca, 211
Marcus FI. Digoxin is effective, but is it safe?, 893
Marra F, *see* Gentillini, 81
Martelli E Arrigoni, *see* Corsico, 241
Massart DL, *see* Vercruysse, 721
Matta F, *see* Tubaro, 809
Mattioli G, *see* Tubaro, 809
Mazzella H. Hydrogen peroxide reduces arterial pressure and respiration in the anesthetized dog, 731
Melandri G, *see* Galie, 337
Metra M, *see* Die Cas, 103
Meyer TE, Adnams C, Commerford P. Comparison of the efficacy of atenolol and its combination with slow-release nifedipine in chronic stable angina, 909
Miccheli A, *see* Corsico, 241
Milazzotto F, *see* Tubaro, 817
Minami N, *see* Tsunoda, 253
Misawa S, *see* Tsunoda, 253
Mitamura H, *see* Ogawa, 621
Mitchell ABS. Hypertension—a disease or a state of doctors' minds, 733
Mitha AS, *see* Patel, 97
Miyabo S, *see* Fujiwara, 365
Miyakita Y, *see* Watanabe, 923
Miyazaki H, *see* Inoue, 373
Morand P, *see* Gibelin, 333
Moravec J, *see* El Alaoui-Talibi, 357
Mori T, *see* Satoh, 691
Morita T, *see* Saso, 257
Munakata M, *see* Tsunoda, 253
Murata K, *see* Kanda, 795
Myrdal U, *see* Leppert, 901

Nakagawa M, *see* Inoue, 373
Nakai T, *see* Fujiwara, 365
Nakayama K, *see* Hiraoka, 593
Nardone A, *see* Corsico, 241
Natale E, *see* Tubaro, 809
Nazzaro P, *see* Vulpis, 899
Nelson MT, Brayden JE. Regulation of arterial tone by calcium-dependent K^+ channels and ATP-sensitive K^+ channels, 605
Nilsson H, *see* Leppert, 901
Noble MIM, *see* Belcher, 149
Noma A. Gating properties of ATP-sensitive K^+ channels in the heart, 515

Odawara A, *see* Saso, 257
Ogawa S, Mitamura H, Katoh H. Effect of E-4031, a new class III antiarrhythmic drug, on reentrant ventricular arrhythmias: comparison with conventional class I drugs, 621
Ohshima M, *see* Watanabe, 923
Ohtani A, *see* Saso, 257
Oida K, *see* Fujiwara, 365
Okada Y, *see* Yanagisawa, 565
Oliver MF. Lowering cholesterol for prevention of coronary heart disease—problems and perspectives, 785
Oliver MF, *see* Wright, 929
Omata K, *see* Tsunoda, 253
Omori I, *see* Inoue, 373
Omvik P, Lund-Johansen P, Haugland H. Modest antihypertensive effect of epanolol, a $beta_1$-selective receptor blocker with $beta_1$ agonist activity: an acute and long-term hemodynamic study at rest and during exercise and double crossover comparison with atenolol on ambulatory blood pressure, 125
Omvik P, Lund-Johansen P. Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin, 193
Opie LH. Calcium antagonists for congestive heart failure: is it really one bridge too far to cross?, 93
Opie LH. Cholesterol confusion in primary prevention of coronary artery disease, 779
Opie LH. Modulation of ischemia by regulation of the ATP-sensitive potassium channel, 507
Opie LH. The origin and significance of our supplements—a response to the New England Journal of Medicine, 491
Orita H, Fukasawa M, Hirooka S, Uchino H, Fukui K, Kohi M, Washio M. In vitro evaluation evaluation of diltiazem on hypotermic injury to immature myocytes, 713
Osterziel KJ, Dietz R. Dosing of ACE inhibitors in postinfarct protection, 881

Packer M. Calcium antagonists for congestive heart failure: evolving concepts in bridge building, 95
Padrini R, *see* Zeppellini, 325
Paoletti R, *see* Franceschini, 297
Parmley W, *see* Chatterjee, 383
Patel JJ, Mitha AS, Sareli P, de Vaal JB. Intravenous fenoldopam infusion in severe heart failure, 97
Pauciullo P, *see* Rubba, 767
Pesce D, *see* Corsico, 241
Petitto M, *see* Di Somma, 119
Piovan D, *see* Zeppellini, 325
Pirelli A, *see* Vulpis, 899
Pitt B, *see* Texter, 273
Po S, *see* Bennett, 585
Pouleur H. High or low dose of angiotensin-converting enzyme inhibitor in patients with left ventricular dysfunction?, 891
Proclemer A, Facchin A, Vanuzzo D, Feruglio GA. Risk stratification and prognosis of patients treated with amiodarone for malignant ventricular tachyarrhythmias after myocardial infarction, 683
Pucheu S, Coudray C, Tresallet N, Favier A, de Leiris J. Effect of iron overload in the isolated ischemic and reperfused rat heart, 701

Rapezzi C, *see* Galie, 337
Rappaport E, *see* Chatterjee, 383
Rasmussen V, *see* Larsen, 915
Ratheiser K, *see* Giebisch, 11
Rector TS. Assurance against drug-induced death in patients with heart failure, 829
Reicher-Reiss H, *see* Mandelzweig, 117
Reyes AJ (ed). Diuretics: clinical pharmacology and uses in cardiovascular medicine, nephrology and heptology, 287
Reyes AJ. Introduction by the guest editor: diuretics in cardiovascular medicine: new wine into old bottles. Presentation of the fundamentals, 7
Reyes AJ, Leary WP. Clinicopharmacological reappraisal of the potency of diuretics, 23
Reyes AJ, Leary WP. Renal excretory responses to single and repeated administration of diuretics in healthy subjects. Clinical connotations, 29
Reyes AJ. Loop diuretics versus others in the treatment of congestive heart failure after myocardial infarction, 869
Ricciardelli B, *see* De Luca, 211
Ricci R, *see* Tubaro, 817
Ricci S, *see* Vulpis, 899
Ringqvist I, *see* Leppert, 901
Robillon JF, *see* Gibelin, 333
Roelandt JRTC, *see* de Jong, 677
Romanelli RG, *see* Gentilini, 81
Rossouw JE, Gotto, Jr. AM. Does low cholesterol cause death?, 789
Rubba P, Pauciullo P, Mancini M. Lowering blood lipids to treat atherosclerosis: vascular tone, plaques, events and mortality, 677
Rubba P, *see* Mancini, 775
Rudy DR, *see* Brater, 69
Ryden L, *see* Kobayashi, 159

Sabbah HN, Levine TB, Gheorghiade M, Kono T, Goldstein S. Hemodynamic response of a canine model of chronic heart failure to intravenous dobutamine, nitroprusside, enalaprilat and digoxin, 349
Sakei R, *see* Inoue, 373
Sakuma H, *see* Tsunoda, 253
Sareli P, *see* Patel, 97
Saarimaa H, *see* Kaila, 839
Saso Y, Ohtani A, Odawara A, Iwasaki H, Takashima K, Morita T. Inhibitory effect of clentiazem (TA-3090), a new calcium antagonist, on balloon catheter-induced intimal thickening of rabbit aorta, 257
Satoh K, Mori T, Yamada H, Taira N. Nicorandil as a nitrate, and cromakalim as a potassium channel opener, dilate isolated porcine large coronary arteries in an agonist-nonselective manner, 691
Sato T, Arita M, Kiyosue T. Differential mechanism of block of palmitoyl lysophosphatidylcholine and of palmitoylcarnitine on inward rectifier K^+ channels of guinea-pig ventricular myocytes, 575
Savonitto S, *see* De Luca, 211
Sawanobori T, *see* Hiraoka, 593
Scheinman M, *see* Chatterjee, 383
Schmidt TA, Holm-Nielsen P, Kjeldsen K. Human skeletal muscle digitalis glycoside receptors (Na, K-ATPase)—importance during digitalization, 175
Schoors DF, *see* Vercruysse, 721
Seccia TM, *see* Vulpis, 899
Sharpe N. ACE inhibitors versus diuretics: when to choose which drug?, 877
Sherry KM, Locke TJ. Use of milrinone in cardiac surgical patients, 671
Shibata A, *see* Watanabe, 923
Shirayama T, *see* Inoue, 373
Sica DA, *see* Brater, 69
Silke B. Central hemodynamic effects of diuretic therapy in chronic heart failure, 45
Sirtori CR, Colli S. Influences of lipid-modifying agents on hemostasis, 817
Sjoquist P-O, *see* Kobayashi, 159
Snyders DJ, *see* Bennett, 585
Sørensen EV, *see* Bøtker, 111
Sørum C, *see* Larsen, 915
Spagnoli LG, *see* Corsico, 241
Suzuki M, *see* Watanabe, 923
Suzuki T, *see* Kanda, 795
Sylvén C. Mechanisms of pain in angina pectoris—a critical review of the adenosine hypothesis, 745

Tadokoro H, *see* Kobayashi, 159
Taira N, *see* Satoh, 691
Takahashi M, *see* Watanabe, 923
Takahashi T, Fukai T, Hata H, Kasuya H, Kuga T, Egashira K, Takashita A. Effects of a new calcium antagonist CD-832, on experimental coronary artery spasm in miniature pigs, 265
Takashima K, *see* Saso, 257
Takashita A, *see* Takahashi, 265
Tamai T, *see* Fujiwara, 365
Tamkun MM, *see* Bennett, 585
Tatsumi, *see* Inoue, 373
Taylor SH. Diuretics and postinfarction heart failure, 885
Ten Eick RE, Zhang K, Harvey RD, Bassett AL. Enhanced functional expression of transient outward current in hypertrophied feline myocytes, 611
Texter M, Lees R, Pitt B, Dinsmore R, Uprichard ACG. The QUinapril Ischemic Event trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention, 273
Timour Q, *see* Aupetit, 217
Tresallet N, *see* Pucheu, 701
Trimarco B, *see* De Luca, 211
Tsialtas D, *see* Zeppellini, 325
Tsunoda K, Abe K, Omata K, Hagino T, Minami N, Munakata M, Yoshida K, Sakuma H, Misawa S, Arima S, Imai Y, Yoshinaga K. Preliminary communication effects of cicletanine on the urinary excretion of prostanoids and kallikrein, and on renal function in man, 253
Tubaro M, Mattioli G, Matta F, Cappello C, Natale E, Ricci R, Gerardi P, Milazzotto F. Defibrotide versus heparin in the prevention of coronary reocclusion after thrombolysis in acute myocardial infarction, 809

Uchino H, *see* Orita, 713
Unwin R, *see* Giebisch, 11
Uprichard ACG, *see* Texter, 273

van Meegan JR, *see* Koning, 801
Vanuzzo D, *see* Proclemer, 683
Venkatesh N, *see* Weiss, 499
Vercruysse I, Schoors DF, Massart DL, Dupont AG. Influences of the calcium antagonists nicardipine and nifedipine, and the calcium agonist BAY-K-8644, on the pharmacokinetics of propranolol in rats, 721
Verdouw PD, *see* Koning, 801
Visioli O, *see* Die Cas, 103
Voelker JR, *see* Brater, 69
Voet D, Afschrift M, Duprez D, De Buyzere M, Barbier F. Influence of isosorbide dinitrate on superior mesenteric artery impedance in humans, 169
Vulpis V, Seccia TM, Ricci S, Nazzaro P, Pirelli A. Study on antihypertensive efficacy of slow-release verapamil: pharmacokinetic and noninvasive hemodynamic profile, 899

Washio M, *see* Orita, 713
Watanabe K, Izumi T, Miyakita Y, Koyama S, Ohshima M, Inomata T, Suzuki M, Takahashi M, Shibata A. Efficacy of amlodipine besilate therapy for variant angina: evaluation by 24-hour Holter monitoring, 923
Weiss JN, Venkatesh N. Metabolic regulation of cardiac ATP-sensitive K^+ channels, 499
Wilde AAM. Role of ATP-sensitive K^+ channel current in ischemia arrhythmias, 521

Wilson PA Poole. Digoxin—doubts to dampen enthusiam, 897
Wright RA, Decroly P, Kharkevitch T, Oliver MF. Exercise tolerance in angina is improved by mivazerol—an alpha$_2$-adrenoreceptor agonist, 929
Wu C-C, *see* Chen, 133

Xiao CS, *see* Koning, 801

Yamada H, *see* Satoh, 691
Yamagishi T, *see* Yanagisawa, 565
Yamahara Y, *see* Inoue, 373
Yanagisawa T, Yamagishi T, Okada Y. Hyperpolarization induced by K^+ channel openers inhibits Ca^{2+} influx and Ca^{2+} release in coronary artery, 565
Yellon DM, Jennings RB (eds). Myocardial protection: the pathophysiology of reperfusion and reperfusion injury, 185
Yellon DM, *see* Baxter, 225
Yoshida K, *see* Tsunoda, 253
Yoshinaga K, *see* Tsunoda, 253

Zeppellini R, Bolognesi R, Javernaro A, DeDomenico R, Libardoni M, Tsialtas D, Piovan D, Padrini R, Cucchini F. Effect of dobutamine on left ventricular relaxation and filling phase in patients with ischemic heart disease and preserved systolic function, 325
Zhang K, *see* Ten Eick, 611

Subject Index

Absenteeism, newly identified hypertensive employee response, 207
Acebutolol, 304, 305, 307
Acetylation polymorphism, genetic influences on cardiovascular drug metabolism, 311–321
Acetylcholine, potassium channels and arterial tone, 605–609
Acipimox, antilipolytic drug, 299
Acquired immune deficiency syndrome, low cholesterol levels common, 792
Action potential, ATP-sensitive K^+ channel role in action potential shortening and myocardial protection in ischemia, 527–536
Action potential duration (APD)
  shortening caused by ATP-sensitive K^+channel antagonists, 499–504
  use-dependent block of the delayed K^+ current in rabbit ventricular myocytes, 599–603
Action potential frequency, use-dependent block of the delayed K^+ current in rabbit ventricular myocytes, 599–603
Acute myocardial infarction (AMI)
  and anticoagulation, 284–285
  defibrotide vs. heparin to prevent coronary reocclusion after thrombolysis, 809–814
  diuretic therapy and acute hemodynamic actions, 46
  nifedipine not improving survival in patients without heart failure, 117–118
  verapamil prevention of sudden death in patients with increased heart size, 381–382
Acylated plasminogen streptokinase activator complex (APSAC), 825–826
Adenosine
  analgesic effects, 750
  antagonized by aminophylline, 139
  biological actions, spectrum of, 749
  dose-response relationships for provoked chest pains, 752
  interactions with other drugs, 145
  neuromodulatory actions, spectrum of, 750
  as pain messenger for angina pectoris, 745–756
  potentiated by dipyridamole, 139
  provoking of atrial fibrillation, 145
  therapeutic and diagnostic cardiac electrophysiological uses, 139–145
  vs. verapamil, 145
Adibendan, 656
Adrenaline
  effect on rat heart response to adrenergic stimulants after cardioplegic arrest, 851–860
  infused after trimetazidine administration to reestablish cyclic flow reductions, 150, 152, 153, 154
Adrenergic stimulants, beta-blocker and Ca^{2+} antagonist effect on rat heart response to (after cardioplegic arrest), 851–860
Advanced renal failure, torasemide effectiveness in a dose-dependent manner, 75–79
Airways hyperreactivity, inhibited by potassium channel openers in peripheral vascular disease and asthma, 555–562
Ajmaline, with quinidine, 319
Aldosterone, 36–37
All cause mortality, cholesterol lowering for prevention of coronary heart disease, 785–788
Allen's method, 258
Almokalant, use-dependent block of the delayed K^+ current in rabbit ventricular myocytes, 599–603
Alpha$_2$ adrenoceptor, mivazerol improvement of exercise tolerance in angina, 929–933
Alphamethyldopa, 649
Alpha-receptor blockade, hemodynamics of long-term antihypertensive therapy, 193, 198, 203
Alprenolol, 304, 305
  adverse reactions in poor metabolizers, 313
  eliminated via the sparteine/debrisoquine oxygenase, 312
  oxidative metabolism, 313
Ambulatory blood pressure, epanolol vs. atenolol lowering effect, 125–131
Ambulatory ECG monitoring, anipamil prevention of ST depression with angina pectoris, 915–920
American Heart Association Meeting, New Orleans (Nov.16–19, 1992), comments submitted by an editorial board member, 283–285
Amiloride, 23, 26, 62, 875
  longer term hemodynamic effects, 47–48
  oral administration effects (various doses) on 24-hour urinary sodium output in healthy subjects, 25
  reducing potassium secretion, 15
  with hydrochlorothiazide, vs. torasemide for hypertension, 65, 67
Aminophylline, adenosine effects antagonized by, 139, 140, 144, 145
Amiodarone
  for ventricular tachycardia (VT) or ventricular fibrillation (VF), after myocardial infarction, 683–688
  interaction with adenosine, 145
  use-dependent block of the delayed K^+ current in rabbit ventricular myocytes, 599–603
  with a second antiarrhythmic drug, 684
Amlodipine
  evaluation by 24-hour Holter monitoring for variant angina, 923–928
  favorable neurohormonal effects in heart failure patients, 95
  for congestive heart failure patients, 93–94
  hemodynamics of long-term antihypertensive therapy, 193–194, 195, 196, 197, 198, 199
  PRAISE study, 284
Amrinone
  for heart failure, 665
  long-term risks and short-term benefits, 655–659
Angina pectoris
  anipamil prevention of ST depression, 915–920
  clinical characteristics, 745–746
  comparative efficacy of partial agonists, 307
  epanolol usefulness, 126, 131
  history, 745
  mivazerol improvement of exercise tolerance, 929–933
  nicorandil's and cromakalim's effects on the coronary artery, 691–698
  trimetazidine as antianginal drug, 149
Angiography
  dietary intervention group results with hypercholesterolemia, 770
  methods of, 276–277, 279
Angiotensin converting enzyme (ACE) inhibitors
  appropriate dosage for left ventricular dysfunction and heart failure, 379
  cost-benefit analysis in heart failure, 283
  and diuretic therapy role in postinfarct heart failure, 863–866
  dosing in postinfarct protection, 881–882
  dosing with left ventricular dysfunction, 891–892
  for chronic heart failure, 349–355, 665–666
  hemodynamics of long-term antihypertensive therapy, 199–200

hypertension in the elderly, 649
quinapril evaluated as preventative of atherosclerosis, 273–280
vs. diuretics, 877–879
Angiotensin-I converting enzyme inhibitors, 34
Anion exchange resins, 300
effect on hemostasis, 819–820
Anipamil, prevention of ST depression with angina pectoris, 915–920
Antiarrhythmic drugs
adenosine's therapeutic value, 139–145
arrhythmogenicity and intraventricular conduction disorders, 217–223
cloned cardiovascular K^+ channels, 585–591
for heart failure, 666
genetic polymorphism, 315–316
Antiatherosclerosis, isradipine potential effect, 137
Anticoagulants, 825–827
and acute myocardial infarction, 284–285
for heart failure, 666
Antihypertensive drugs, genetic polymorphism, 321
Antihypertensive effect, verapamil (slow-release), 899–900
APP-201-533, 656
Aprindine, vs. E-4031, 622–626
Arrhythmias
ATP-sensitive K^+ channel current role in ischemia, 521–524
phosphodiesterase III inhibitor risks and benefits, 655, 657–659
stretch role in pathogenesis of, 377
Arrhythmogenic effect, antiarrhythmic drugs and intraventricular conduction disorders in pigs, 217–223
Arterial impedance, hypertension in the elderly, 643–650
Arterial smooth muscle cell, nicorandil effects on cell proliferation and cholesteryl ester accumulation, 365–371
Arteries, potassium channels and arterial tone, 605–609
Ascites, torasemide treatment, 81–84
Aspirin, incompleteness of protection from platelet thrombosis, 149, 151, 153, 154, 156
Asthma
contraindication for adenosine use, 139, 144
partial agonists and, 310n
PDE inhibitors as bronchodilators, 659
potassium channel openers' therapeutic potential, 555, 560–562
Asymptomatic Carotid Artery Plaque Study (ACAPS), 771
Atenolol, 304, 305–306, 307, 308, 649
vs. (and combined with) nifedipine in stable angina, 909–913
vs. epanolol, hemodynamic study as antihypertensive, 125–131
Atherosclerosis
blood lipid lowering as treatment, 767–772
clentiazem inhibitory effect on balloon injury of rabbit aorta, 257–263
lipid-modifying agent influences on hemostasis, 817–822
nicorandil effect in rats, 365
progression retarded in hyperlipidemic patients, 297
quinapril as preventative, evaluation in QUinapril Ischemic Event Trial, 273–280
ATP, glibenclamide failure to inhibit the opening of ATP-sensitive K channels, 495–497
ATP-K^+ channel, drug-induced $I_{K,ATP}$ activation, 593–597
ATP-sensitive K^+ channel
activation by K channel openers in vascular smooth muscle cells, 539–545
gating properties, 515–519
in cardiac ischemia protection provided by, altering electric activity, 527–536
metabolic regulation, 499–504
modulation of ischemia, 507–511
potassium channels and arterial tone, 605–609
role in ischemic arrhythmias, 521–524
Atrial fibrillation, adenosine to possibly provoke, 145
Atrial natriuretic factor, with congestive heart failure and loop diuretics, 41
Atrial tachycardia, flecainide acetate effect, 373
Atrioventricular node, adenosine therapeutic uses in arrhythmias, transient blockade, 139–145
Atropine, 752
Australian National Blood Pressure Study, 648
Australian trial, 57
Australian Trial in Mild Hypertension, 727
Autonomic nerves, adenosine as cause of excitation, 750, 754
AV nodal reciprocating tachycardia, flecainide acetate effect, 373
Awareness, screening for hypertension at worksites, 207–209
Azosemide, 23

Balloon injury, clentiazem inhibitory effect on rabbit aorta, 257–263
Bamiphylline, 752, 753, 754
Barium, blocking hyperpolarizations and dilations, 605, 608
BASIS trial, 621
Bay-K-8644
EADs abolished by pinacidil, 511
plus propranolol, influence on the pharmacokinetics in rats, 721–725
to contract cromakalim, 691–697
Benazepril, hemodynamics in hypertension, 211–215
Benzothiadiazines, 23
Berferine, 656
Beta-adrenergic agonists, effect on delayed rectifier K current by neurotransmitters and magnesium, 547–553
Beta-adrenoceptor antagonists, 313
Beta-adrenergic blockade
effects on rat heart response to adrenergic stimulants after cardioplegic arrest, 851–860
enoximone and metoprolol in severe congestive heart failure, 337, 344–345
metoprolol coronary venous retroinfusion, 159–166
Beta blockers
and adenosine, 752, 754
antagonist activity assessed by extent of $beta_1$- and $beta_2$-receptor occupancy, 839–848
antiproarrhythmic effect, 284
CAST study, 284
epanolol antihypertensive effect, 125–131
hypertension in the elderly, 650
interaction with adenosine, 145
partial agonism, 303–308
Beta-receptor blockade, hemodynamics of long-term antihypertensive therapy, 193, 197–198, 201, 202–203
$Beta_1$ receptors, antagonist activity assessed of metoprolol, pindolol, and propranolol in the elderly, 839–848
$Beta_2$ receptors, antagonist activity assessed of metoprolol, pindolol, and propranolol in the elderly, 839–848
Bezafibrate, 299
effect on hemostasis, 818, 819
Bimakalim, to activate glibenclamide, 495–496, 497
Bisoprolol, 305, 307
Bonferoni's method, 351
Bopindolol, 305
Bufuralol
adverse reactions in poor metabolizers, 313
eliminated via the sparteine/debrisoquine oxygenase, 312
genetic polymorphism, 315
oxidative metabolism, 313
Bumetanide, 23
acute hemodynamic actions, 47, 49, 51
vs. torasemide, 72
Bupivacaine, 219
Bupranolol, 307

Caffeine, inducing Ca^{2+} release in coronary artery, 565, 570, 572
Calcific aortic stenosis, 384
Calcitonin gene-related peptide (CGRP), potassium channels and arterial tone, 605–609

Calcium
  urinary excretion after loop diuretic administration, 38
  urinary excretion after thiazide dose, 33
Calcium antagonists
  amlodipine besilate evaluation by 24-hour Holter monitoring for variant angina, 923–928
  anipamil prevention of ST depression with angina pectoris, 915–920
  as antihypertensive agents, 193, 198–199, 203
  DC-832 effect on coronary artery spasm in pigs, 265–270
  clentiazem inhibitory effect on balloon injury of rabbit aorta, 257–263
  genetic polymorphism, 320–321
  in heart failure, 284
  naming of, 183
  nisoldipine effects on hemodynamics, neurohumoral parameters, and functional capacity with chronic heart failure, 103–108
  not recommended by Milton Packer for congestive heart failure, 93–94
  short- and long-term therapy deleterious to patients with chronic heart failure, 95
Calcium channel blockers
  hypertension in the elderly, 649, 650
  isradipine dose titration study in Chinese patients with essential hypertension, 133–138
Ca-dependent K channel, activation by K channel openers in vascular smooth muscle cells, subtypes, 540–542, 543
Ca^{2+}-activated potassium channels, and arterial tone, 605–609
Ca^{2+} channel blocker, inhibiting cell proliferation and cholesteryl ester accumulation and DNA synthesis, 365–371
Ca^{2+} channels, influx and release vs. K^+ channel openers, 565–572
Ca^{2+} release, vs. K^+ channel openers, 565–572
Calciuresis, torasemide effect in patients with chronic renal failure, 77
CAMIAT trial, 621
Captopril, 36, 58, 215, 307–308
  addition to diuretics for postinfarct heart failure therapy, 865
  clinical trial evaluation, 274
  dosing in postinfarct protection, 881–882
  for heart failure, 665
  hypertension in the elderly, 649–650
  inducing diuresis and natriuresis, 255
  with metoprolol for congestive heart failure in mice, 795–799
Carazolol, 305
Carbamylcholine chloride (CARBACHOL), 631
Carbonyl compounds and $I_{K,ATP}$, 593, 594–595
Cardiac arrhythmia, epanolol usefulness, 131
Cardiac Arrhythmia Suppression Trial (CAST), 217, 284, 599
Cardiac contractility, propionyl-L-carnitine effect on hypertrophied heart, 357–362
Cardiac effects, benazepril in hypertensive patients, 211–215
Cardiac excitation-contraction coupling, molecular and functional diversity of cloned cardiac potassium channels, 585–591
Cardiac hypertrophy
  and enhanced I_{to}, 611–618
  hypertension in the elderly, 643–650
  propionyl-L-carnitine effect on rat hearts, 357–362
Cardiac insufficiency syndrome, 41
Cardiac ischemic events, 276
Cardiac muscle, glibenclamide failure to inhibit the opening of ATP-sensitive K channels, 495–497
Cardiac myocytes
  delayed K^+ current in guinea pig sinoatrial node, 627–634
  diltiazem lack of protective effect on hypothermic injury to immature myocytes, 713–719
  hypertrophy and enhanced I_{to}, 611–618
Cardiac preservation, diltiazem nonprotective effect on hypothermic injury to immature myocytes, 713–719
Cardiac surgery, milrinone use, 671–674
Cardiology, illustrated text/reference (book review), 383
Cardioplegia, beta-blocker and Ca^{2+} antagonist effects on response of rat heart to adrenergic stimulants after cardioplegic arrest, 851–860
Cardioprotection, ATP-sensitive K^+ channels in cardiac ischemia, 527–536
Cardiothoracic (CT) index, 381–382
Cardiovascular, genetic influences on drug metabolism, 311–321
Cardiovascular risk, cholesterol confusion in primary prevention of coronary artery disease, 779–783
Carotid Atherosclerosis Italian Ultrasound Study (CAIUS), 771
Carteolol, 305, 799
Carvedilol
  as double-action drug, 198
  hemodynamics of long-term antihypertensive therapy, 193–199, 203, 204
  vasodilatory dual action compared to epanolol, 131
Catecholamines, hypertensive labeling, 727–728
CD-832
  chemical structure, 266
  effect on coronary artery spasm in pigs, 265–270
CD-OG115, 656
Ceiling dose, torasemide, 69, 73
Celiprolol, 305, 306–307, 308, 310n
Cell proliferation, nicorandil effect, 365–371
Cell volume regulation, 19–20
Central hemodynamics, epanolol antihypertensive effect, exercise test, 125–131
CGP 12177, 305
CGP 20172a, 307
CGP 20712a, 305
Channel activation, drug-induced $I_{K,ATP}$ activation, 593–597
Charybdotoxin (CTX), potassium channels and arterial tone, 605–609
Child-Pugh classification scheme, cirrhosis patients given torasemide, 82
Chinese, isradipine dose titration study for essential hypertension, 133–138
Chi-square test with Yates' continuity correction (arrhythmia incidence), 226, 229
Chlorothiazide, 55
Chlorthalidone, 23, 67
Cholesterol
  blood lipid lowering as treatment for atherosclerosis, 767–772
  confusion in primary prevention of coronary artery disease, 779–783
  low cholesterol as cause of deaths, 789–793
  treatment of mild hypercholesterolemia in the absence of overt cardiovascular disease, 775–776
Cholesterol-Lowering Atherosclerosis Study (CLAS), 768, 770, 779
Cholesteryl ester accumulation, nicorandil effect, 365–371
Chronic heart failure
  diuretic drug improvement of central hemodynamic effects, 45–52
  milrinone use in cardiac surgical patients, 671–674
Chronic renal failure, torasemide dose-response relationship, 76–77
Chronic stable angina, atenolol vs. (and combined with) nifedipine in stable angina, 909–913
CI-914, 656
CI-930, 656
Cibenzoline, arrhythmogenicity and intraventricular conduction disorders, 217, 219, 220, 222, 223
Cicletanine, 23, 24–25
  natriuretic action and prostaglandins, 253–256
  natriuretic effect abolished by indomethacin, 255
  oral administration effects (various doses) on 24-hour urinary sodium output in healthy subjects, 25
Cilazapril, MERCATOR clinical trial evaluation, 273
Cine film, 276–277

Ciprofibrate, 299
  effect on hemostasis, 819
Circadian rhythm, thiazides vs. torasemide for hypertension, 66, 67
Cirrhosis
  torasemide and serum half-life values, 69–73
  torasemide treatment, 81–84
Class III antiarrhythmic agent, E-4031 effect on reentrant ventricular arrhythmias, 621–626
Clentiazem
  chemical structure, 258
  inhibitory effect on balloon catheter-induced intimal thickening of rabbit aorta, 257–263
  vs. diltiazem, 257, 259, 260, 261, 262–263
Clinical trials, QUinapril Ischemic Event Trial (QUIET), 273–280
Clofibrate
  for hypertriglyceridemia, 299
  influences on hemostasis, 818, 819
Clofilium, 632
Clonidine, 752
Clopamide, 23, 24
  oral administration effects (various doses) on 24-hour urinary sodium output in healthy subjects, 25
Clorexolone, 23
Coagulation, trimetazidine effect, 155–156
Cold pressor test (CPT), Raynaud's patient sympathetic activation after nifedipine treatment, 901–906
Collateral blood flow, hemodynamic effects in peripheral vascular disease and asthma, potassium channel openers' therapy, 556, 558–559
Concentration jump experiment, gating properties of ATP-sensitive K^+ channels, 515–519
Confounding factors, low cholesterol as cause of deaths, 789–793
Congestive heart failure
  calcium antagonist negative inotropic effect, 93–94
  calcium antagonist short- and long-term therapy, 95
  decompensated, and urinary sodium excretion after loop diuretic administration, 35–36
  definition, 661
  enoximone effect alone and with metoprolol, 337–345
  hypertension in the elderly, 649–650
  isosorbide dinitrate effect on superior mesenteric artery impedance, 172
  loop diuretics, 40–41
  loop diuretics in treatment of, 8–9
  loop diuretics vs. others in treatment after myocardial infarction, 869–875
  metoprolol with captopril therapy in mice, 795–799
  torasemide and serum half-life values, 69, 72
  xamoterol renal function effects, 111–115
CONSENSUS trials, 795, 865
  I, 881
  II, 882
Contractility, dobutamine and improvement of ventricular relaxation, 325–329
Coronary angioplasty, metoprolol intravenously given to patients with single-vessel coronary artery disease, 677–681
Coronary artery, hyperpolarization induced by K^+ channel openers inhibiting Ca^{2+} release, 565–572
Coronary artery bypass grafting (CABG), 276
Coronary artery bypass surgery, beta-blocker and Ca^{2+} antagonist effects on rat heart response to adrenergic stimulants after cardioplegic arrest, 851–860
Coronary artery disease
  cholesterol confusion in primary prevention, 779–783
  dobutamine effect on left ventricular relaxation and filling phase, 325–329
  in women, 283
  metoprolol intravenously given during angioplasty, 677–681
  quinapril evaluation after coronary artery intervention, 273–280
Coronary artery spasm, CD-832 effect in pigs, 265–270
Coronary blood flow
  enoximone effect alone and with metoprolol, 341–344
  increase as cause of antianginal activity of nicorandil, 122
Coronary Drug Project, 771–772
Coronary heart disease (CHD)
  blood lipid lowering as treatment for atherosclerosis, 767–772
  dyslipidemic syndrome and, 297
Coronary heart disease prevention, serum lipid modification, 761–764
Coronary Heart Disease Prevention Model, 763
Coronary thrombosis, trimetazidine effects, measurement of cyclic flow reductions, 149–156
Coronary venous retroinfusion, metoprolol effect on infarct size, 159–166
Cox Proportional Hazards models, 279
Creatinine clearance, torasemide half-life and, 71
Cromakalim
  activation of K channels in vascular smooth muscle cells, 539–545
  chemical structure, 540
  effects on the coronary artery, 691–698
  hemodynamic effects in peripheral vascular disease, 556–560, 562
  K ATP current and ischemic arrhythmias affected, 523
  potassium channels and arterial tone, 605–609
  role in ischemia, 510, 511
  vs. Ca^{2+} influx and release, 565–572
Cyclic adenosine monophosphate (AMP), phosphodiesterase III inhibitor risks and benefits, 655–659
Cyclic flow reductions (CFRs), trimetazidine effects on in vivo coronary arterial platelet thrombosis, 149–156
Cyclopenthiazide, with propranolol, 315
Cycloxygenase inhibition, 752
Cytoplasmic Ca^{2+} concentration, influx and release affected by K^+ channel openers inducing hyperpolarization, 565–572

D13625, 656
Darodipine, hemodynamic effects in peripheral vascular disease, 556
DAVIT II study, 93
  with verapamil, 381–382
Death, assurance against drug-induced death in heart failure patients, 829–830
Debrisoquine
  eliminated via the sparteine/debrisoquine oxygenase, 312
  potential therapeutic implications of poor vs. extensive metabolizer status, 312
Debrisoquine/sparteine polymorphism, genetic influences on cardiovascular drug metabolism, 311–321
Declaration of Helsinki, 275
Deferoxamine, iron overload in ischemic and reperfused rat heart, 702, 704, 705, 708, 709
Defibrotide, vs. heparin to prevent coronary reocclusion after thrombolysis in acute myocardial infarction, 809–814
Delayed rectifier
  K current regulation by neurotransmitters and magnesium, 547–553
  voltage-gated cloned cardiovascular K^+ channels, 585–591
Delayed rectifier K^+ current, in guinea pig sinoatrial node, 627–634
Dextromethorphan, 311
Dextrorphan, 311
Diabetes
  and hypercholesterolemia, 775–776
  and hypertriglyceridemia, 299, 300
Diabetes mellitus, and hypertension in the elderly, 649
Diapamide, 23
Diastolic phase, dobutamine effect, 325–329
Diazepam, cyclic flow reductions occurring in humans sedated by, 155

Diazoxide, 56
activation of K channels in vascular smooth muscle cells, 539–545
potassium channels and arterial tone, 605–609
Dichloroisoprenaline, 304, 305, 306
Dichloroproterenol, 304
Diet
and low cholesterol levels, 792
treatment of mild hypercholesterolemia in the absence of overt cardiovascular disease, 775–776
Digitalis
digoxin safety, 893–895
effect on left ventricular relaxation, 328
Digitalis glycosides, human skeletal muscle receptors (Na, K-ATPase), importance during digitalization, 175–180
Digitalization, human skeletal muscle digitalis glycoside receptors (Na, K-ATPase) importance, 175–180
Digoxin
for heart failure, 664–665
hemodynamic response in dogs with chronic heart failure, 349–355
in heart failure, 284
interaction with adenosine, 145
safety, 893–895
safety controversy, 897–898
Dihydralazine, potassium channel openers' therapeutic potential in peripheral vascular disease, 556
Dilazep, 754
Dilevalol, 305, 307
as double-action drug, 198
hemodynamics of long-term antihypertensive therapy, 193–198, 203, 204
vasodilatory dual action compared to epanolol, 131
Diltiazem
benefit limited to patients free of congestive heart failure, 117
hemodynamics of long-term antihypertensive therapy, 193–199
hypertension in the elderly, 650
and hypertrophied myocardium in rats, 225–230
inhibiting cell proliferation in rat hearts, 366–369
lack of protective effect on hypothermic injury, 713–719
vs. clentiazem, 257, 259, 260, 261, 262–263
vs. flecainide, 222
with metoprolol, 314
Dinitrophenol, to activate glibenclamide, 495–496
Dipyridamole, 751–752, 754
adenosine effects potentiated by, 139, 145
Disopyramide
interaction with adenosine, 145
use-dependent block of the delayed K^+ current in rabbit ventricular myocytes, 599–603
vs. antiarrhythmic drugs, 222
vs. E-4031, 622–626
Distal impedance, 172
Diuresis, fenoldopam intravenous infusion in severe heart failure, 99
Diuretic potency, 26
Diuretic resistance, torasemide in patients with chronic renal insufficiency, 69–73
Diuretics
acute hemodynamic actions, 46–47
antihypertensive efficacy, 57
antihypertensive mechanisms, 55–56
central hemodynamic effects in chronic heart failure, 45–52
classes of, 23
clinical pharmacology and uses in cardiovascular medicine, nephrology and hepatology (book review), 287
clinicopharmacological reappraisal of potency, 23–27
essential hypertension, 39–40
for heart failure, 664
heterogeneity of the antihypertensive response to, 56–57
in postinfarction heart failure, 885–888
interactions between proximal and distal ion and fluid transport, 15
ischemic heart disease and, 57, 58, 59
longer term hemodynamic effects, 47–48
loop diuretics vs. others in congestive heart failure treatment after myocardial infarction, 869–875
metabolic complications, 57–59
potency and effects on renal handlings of chloride and potassium, 26
renal excretory potency, definition, 23–24
renal excretory responses to single and repeated administration in healthy subjects, 29–41
therapy role in postinfarct heart failure, 863–866
torasemide in patients with chronic renal insufficiency, 69–73
torasemide therapy, 7–9
volume and humoral consequences in heart failure, 45–46
vs. ACE inhibitors, 877–879
DNA synthesis, prevented by Ca^{2+} channel blockers, 370, 371
Dobutamine
effect on rat heart response to adrenergic stimulants after cardioplegic arrest, 851–860
hemodynamic response in dogs with chronic heart failure, 349–355
and ventricular relaxation, 325–329
Dofetilide, use-dependent block of the delayed K^+ current in rabbit ventricular myocytes, 599–603
Dogs
digoxin, dobutamine, enalaprilat and nitroprusside effects on chronic heart failure in dogs, 349–355
propranolol infarct size reduction, 165
trimetazidine effects on in vivo coronary arterial platelet thrombosis, 149–156
Dopamine receptors, fenoldopam intravenous infusion in severe heart failure, 97–101
Dosing, ACE inhibitors in postinfarct protection, 881–882
Downregulation phenomenon of myocardial beta-receptors, 335
Doxazosin, hemodynamics of long-term antihypertensive therapy, 193–198, 203
DPI-2010106, 656
Drug metabolism, genetic influences, 311–321
Drugs affecting lipid metabolism, influences on hemostasis, 817–822
Drug therapy
low cholesterol as cause of death, 789–793
quinapril evaluated after coronary artery intervention, 273–280
d-sotalol, 237–238
Duplex ultrasound, to investigate isosorbide dinitrate influence on splanchnic circulation in humans, 169–174
Dutch Multicenter Study, 687, 688
Dysbetalipoproteinemia, 299
Dyslipidemic syndrome, 297

E-4031
effect on reperfusion arrhythmias and QT interval in rats, 233–239
use-dependent block of the delayed K^+ current in rabbit ventricular myocytes, 599–603
vs. aprindine, 622–626
vs. disopyramide, 622–626
vs. flecainide, 622–626
vs. propranolol, 622–626
with tedisamil, 236–239
Early afterdepolarizations (EADs), proarrhythmic vs. antiarrhythmic effects, 511
Early-afterdosing diuretic effect, 36, 37
Early hypertension, hypertensive labeling, 727–728
Effective refractory period (ERP), 373
Effort angina, nicorandil vs. metoprolol, 119–123
Elderly
antagonist activity assessed of metoprolol, pindolol and propranolol by extent of $beta_1$- and $beta_2$-receptor occupancy, 839–848
geriatric cardiology (book review), 383–384

hypertension as a disease or as a state of doctors' minds, 733–734
torasemide vs. thiazides for hypertension, 66
Elderly hypertensive, disease-related complications and therapeutic implications, 643–650
Electrocardiography, monitoring during coronary angioplasty, 678–679, 680–681
Electrophysiological effects, flecainide acetate on stretched guinea pig left atrial muscle, 373–378
Enalapril, 307–308
clinical trial evaluation, 273–274
cost-benefit analysis in heart failure, 283
dosing in postinfarct protection, 881–882
for heart failure, 665
hypertension in the elderly, 649–650
Enalaprilat, hemodynamic response in dogs with chronic heart failure, 349–355
Encainide, 311
eliminated via the sparteine/debrisoquine oxygenase, 312
genetic polymorphism, 316–317
pharmacologic response, 321
potential therapeutic implications of poor vs. extensive metabolizer status, 312
use-dependent block of the delayed K^+ current in rabbit ventricular myocytes, 599–603
with quinidine, 319
Encephalomyocarditis virus, metoprolol with captopril for congestive heart failure in mice as result of virus inoculation, 795–799
Endothelial-derived hyperpolarizing factor (EDHF), potassium channels and arterial tone, 605–609
Endothelin, 691, 692, 693, 694, 695, 697
Endothelium dependent relaxation, blood lipid lowering as treatment for atherosclerosis, 767–772
End-stage renal disease, torasemide effect, 75–79
Energy metabolism, propionyl-L-carnitine effect on rats, 241–251
Enoximone
for congestive heart failure, alone and with metoprolol, 337–345
for heart failure, 665
hemodynamics of prolonged infusion in heart failure patients, 333–335
long-term risks and short-term benefits, 656–659
Epanolol, 304, 307, 308
chemical structure, 126
hemodynamics in patients with essential hypertension, 303
hemodynamics of long-term antihypertensive therapy, 193–198, 203
vs. atenolol, hemodynamic study as antihypertensive, 125–131
Epidemiology, low cholesterol as cause of deaths, 789–793
Essential hypertension
antihypertensive treatment with loop diuretics, 8
early distal tubular diuretics, 39–40
epanolol hemodynamic effects, 125–131
in elderly, 643–650
isradipine dose titration study in Chinese patients, 133–138
ESVEM trial, 621
Ethacrynic acid, 23
Etozoline, 23
European Atherosclerosis Society, guidelines for CHD prevention, 298
European milrinone trial, 674
European Working Party on High Blood Pressure in the Elderly (study), 648
EWPHE trial, 57
Exercise
diltiazem for long-term antihypertensive therapy, 199, 203
epanolol vs. atenolol hemodynamic study as antihypertensive, 125–131
sodium restriction and hemodynamics of long-term antihypertensive therapy, 197, 200, 203
Exercise test, antiischemic effects of nicorandil vs. metoprolol, 119–123
Exercise tolerance, mivazerol improvement of exercise tolerance in angina, 929–933
Expanolol, 305
Experimental arteriopathy, propionyl-L-carnitine effect on rats, 241–251
External work, trimetazidine (intracoronary effect on regional function of repeated ischemia in pigs, 801, 805
Extrinsic pathway inhibitor (EPI), 820

Familial Atherosclerosis Treatment Study (FATS), 768–769, 779
Felodipine
favorable neurohormonal effects in patients with heart failure, 95
for congestive heart failure patients, 93
hemodynamics of long-term antihypertensive therapy, 193–194, 195, 196, 197, 198
hypertension in the elderly, 650
VeHFT III trial, 284
Fenofibrate, 299
effect on hemostasis, 819
Fenoldopam, intravenous infusion in severe heart failure, 97–101
Fibrates, fibric acid derivatives for treatment of hypertriglyceridemia, 297, 299, 300
Fibric acids, influences on hemostasis, 817–822
Fibrin, thrombolytic therapy, 825–827
Flecainide, 311
arrhythmogenicity and intraventricular conduction disorders, 217–223
eliminated via the sparteine/debrisoquine oxygenase, 312
genetic polymorphism, 317
interaction with adenosine, 145
potential therapeutic implications of poor vs. extensive metabolizer status, 312
vs. E-4031, 622–626
with amiodarone, 684
Flecainide acetate, electrophysiological effects on stretched guinea pig left atrial muscle, 373–378
Fleckenstein, Albrecht, obituary, 183
Fluid excretion, advanced renal failure patients and torasemide effect, 75–79
Folch's method, 258
Folts' model, coronary artery stenosis thrombus growth and trimetazidine effects, 149, 155, 156
Framingham heart failure rating method, diuretics and hemodynamic actions, 49
Framingham Heart Study, 57, 643, 649, 792, 865
Frank-Starling mechanism, 671, 672–673, 863
Free radicals, hydrogen peroxide reducing arterial pressure and respiration in the anesthetized dog, 731–732
Frenquizone, 23
Frusemide
acute hemodynamic actions, 46, 47
diuretics in postinfarction heart failure, 885–888
for heart failure, 664
therapy role in postinfarct heart failure, 864
Fura-2 method, K^+ channel opener vasodilating mechanisms examined by measurement of Ca^{2+} concentration, 565, 566, 568
Furosemide, 23, 26, 59
congestive heart failure and, 41
in advanced renal failure, 75–76
inducing diuresis and natriuresis, 255
loop diuretics vs. others in congestive heart failure treatment after myocardial infarction, 869–875
oral administration effects (various doses) on 24-hour urinary sodium output in healthy subjects, 25
renal effects, 11–20
renal excretory responses, 36
vs. torasemide, 72, 75, 76–79
vs. torasemide in cirrhosis and ascites patients, 81–84
Future policies, cholesterol lowering for

prevention of coronary heart disease, 785–788

Gating kinetics, ATP-sensitive K^+ channels in the heart, 515–519
GDP, 544–545
Gemfibrozil, 299
  effect on hemostasis, 818, 819
  for coronary heart disease in hyperlipidemic patients, 297
Genetic polymorphism, debrisoquine/sparteine, cardiovascular drug metabolism, 311
Geriatric cardiology (book review), 383–384
Glibenclamide, 239
  antiarrhythmic effect in initial phase of ischemia, 521, 522, 523, 524
  blocking hyperpolarizations and dilations, 605, 607–608
  effect on action potential duration, 499, 501, 503, 504
  effect on macroscopic membrane current, 541, 543
  failure to inhibit the opening of ATP-sensitive K channels, 495–497
  to antagonize cromakalim, 691, 692, 693, 695, 697
  to block effects induced by pinacidil and nicorandil, 565, 567, 568, 571, 572
  to inhibit varied ischemic injury and cause decline in resting membrane potential, ATP-sensitive K^+ channels, 527–536
  to prolong action potential duration and decrease the incidence of early ventricular arrhythmias, 507–511
Glucose intolerance, diuretics and, 58
Glutathione peroxidase (GPX), 701, 705, 709
Glycolysis
  regulation of the cardiac ATP-sensitive potassium channel, 509–510
  selective inhibition in ATP-sensitive K^+ channels, 499–504
Guinea-pig left atrial muscle, flecainide acetate electrophysiological effects, 373–378
Guinea pigs, cardiac ATP-sensitive K^+ channels, 502
Guinea-pig ventricular cell, lymphosphatidylcholine and palmitoylcarnitine effects on inward rectifier K^+ current, 575–583

Haber's method, 254
Hassle compound, 304
(—)-[^{3}H] CGP-12177 (radiolabeled beta-antagonist), $beta_1$- and $beta_2$-receptor occupancy in plasma, antagonist activity of metoprolol, pindolol, and propranolol in the elderly, 839–848
Heart
  delayed rectifier K current regulation by neurotransmitters and magnesium, 547–553
  structure (book review of text and color atlas), 288
Heart failure
  ACE inhibitor dosing in patients with left ventricular dysfunction, 891–892
  ACE inhibitors vs. diuretics, 877–879
  assurance against drug-induced death, 829–830
  calcium antagonist therapy, 284
  cost-benefit analysis of ACE inhibitors, 283
  diagnosis, 663
  digoxin safety, 893–895
  digoxin safety controversy, 897–898
  digoxin therapy, 284
  diuretics in postinfarction heart failure, 885–888
  diuretic therapy role in postinfarct heart failure, 863–866
  drug treatment, 664–667
  effort intolerance and physical training, 663–664
  enoximone, hemodynamics of prolonged infusion, 333–335
  epidemiology, 662–663
  fenoldopam intravenous infusion, 97–101
  hemodynamic response in dogs of IV dobutamine, nitroprusside, enalaprilat and digoxin, 349–355
  management, 663
  management and definition of, 661–667
  nisoldipine effects on hemodynamics, neurohumoral parameters, and functional capacity, 103–108
  pathophysiology, 662
  prognosis, 662–663
Helsinki Heart Study, 782
  gemfibrozil effectiveness for coronary heart disease in hyperlipidemic patients, 297
Hemodialysis patients, torasemide in patients with advanced renal failure, 75
Hemodynamics
  benazepril in hypertensive patients, 211–215
  digoxin, dobutamine, enalaprilat and nitroprusside effects on chronic heart failure in dogs, 349–355
  diuretic therapy, historical review of, 55–62
  diuretics in postinfarction heart failure, 885–888
  enoximone prolonged infusion in heart failure patients, 333–335
  fenoldopam intravenous infusion in severe heart failure, 98, 99, 100–101
  long-term effects of newer antihypertensive agents (epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin), 193–204
Heparin
  intravenous vs. subcutaneous, 284
  in unstable angina pectoris, 284
  vs. defibrotide to prevent coronary reocclusion after thrombolysis in acute myocardial infarction, 809–814
Hepatic encephalopathy, 82
High energy phosphates, trimetazidine (intracoronary) effect on regional function of repeated ischemia in pigs, 801–807
Hill coefficient, 502, 503, 515, 519, 596
Hirudin, 827
Hirulog, 284, 827
Histamine, 265–270
  to cause contractions for nicorandil and cromakalim evaluation, 691, 693, 694, 697
Histology, propionyl-L-carnitine effect on rats, 241, 245–249
HMG-CoA reductase inhibitors (statins), 300, 782
  effect on hemostasis, 819–820
Holter electrocardiogram, amlodipine besilate evaluation for variant angina, 923–928
Homocystinuria, 821
Honolulu Heart Program, 789–790
^{3}H-ouabain binding, increase in digitalized patients, 175–180
Human embryonic kidney cells (HEK 293), 634
Hydralazine
  acetylation, polymorphic, 312–313
  genetic polymorphism, 321
  hemodynamic effects in peripheral vascular disease, 556
  pharmacologic response, 321
Hydrochlorothiazide (HCTZ), 23, 26, 58, 59, 62
  early-afterdosing effect, 31
  as facultative diuretic, 24
  high-dose diuretic therapy, 8
  loop diuretics vs. others in congestive heart failure treatment after myocardial infarction, 869–875
  oral administration effects (various doses) on 24-hour urinary sodium output in healthy subjects, 25
  renal excretory responses to 25 mg dose, 29–33, 38
  with triamterene, vs. torasemide for hypertension, 65, 66, 67
Hydrogen peroxide, reducing arterial pressure and respiration in the anesthetized dog, 731–732
5-hydroxytryptamine (5-HT), 691–695, 697, 698
Hypercholesterolemia
  cholesterol lowering for prevention of coronary heart disease, 785–788
  HMG CoA reductase drugs, 782
  hypertension in the elderly, 649
  signaling future atherosclerosis, 767–772

Hyperglycemia, diuretic therapy for hypertension, 55, 58
Hyperlipidemia
  diuretic therapy for hypertension, 55
  treatment risks, 761–764
Hypertension
  antihypertensive treatment with loop diuretics, 8
  benazepril hemodynamic effects, 211–215
  and chronic renal insufficiency, 8
  diuretic therapy, historical review of, 55–59
  epanolol vs. atenolol hemodynamic study, 125–131
  and hypercholesterolemia, 775–776
  hypertensive labeling, 729
  long-term hemodynamic effects at rest and during exercise of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol and ketanserin, 193–204
  nicorandil vs. metoprolol antiischemic effects, 119, 120
  partial agonist beta-blockers, 307
  as real disease, 735
  screen on worksite and its therapeutic implications, 207–209
  torasemide effect in advanced renal failure, 75, 76
  torasemide vs. thiazide therapy, 63–67
Hypertension Detection and Follow-up Program, 648, 735
Hypertension diagnosis, hypertension as a disease or as a state of doctors' minds, 733–734
Hypertension in elderly, hypertension as a disease or as a state of doctors' minds, 733–734
Hypertension in females, hypertension as a disease or as a state of doctors' minds, 733–734
Hypertensive labeling, 727–728
  effect on hemodynamics, 729
  psychological and physiological sequelae, 207–209
Hypertensive personality, profile of, 208
Hypertriglyceridemia
  classification scheme, 298
  etiology of, 298
  pharmacological control of, 297–301
Hypocalcemia, 61
Hypokalemia, 9, 32
  diuretic therapy for hypertension, 55, 57–58
  in cirrhosis patients given torasemide, 84
  torasemide vs. thiazides for hypertension, 66–67
Hypomagnesemia, 9
Hyponatremia, diuretics and, 57
Hypothermic injury, diltiazem effect, 713–719
Hypoxanthine, metabolism selection during coronary angioplasty, 678, 680, 681
Hypoxia, action potential duration shortening, 499–504

Iberiotoxin, potassium channels and arterial tone, 605–609
ICI 50172, 304
ICI 118551, 305, 307
Iloprost, 819
Indapamide, 23, 24, 56
  oral administration effects (various doses) on 24-hour urinary sodium output in healthy subjects, 25
Independent risk factor, digoxin safety, 893–895
Index of thrombus formation, 154–155
Indolidan, 656
Indomethacin
  abolishing the natriuretic effect of cicletanine, 255
  hydrogen peroxide reducing arterial pressure and respiration in the anesthetized dog, 731–732
Infarct size, metoprolol not causing reduction in, 159–166
Inodilators, 655
Inosine, 752
Inotropic agents, for heart failure, 664
Inotropic effects, phosphodiesterase III inhibitor risks and benefits, 655–659
Institutional Human Research Review Committee, 326
Intermittent claudication, following ischemic exercise, slower recovery of leg muscle phosphocreatine, 556–557
International Committee for the Evaluation of Hypertriglyceridemia as a Vascular Risk Factor, 298
Intimal thickening, clentiazem inhibitory effect on balloon injury of rabbit aorta, 257–263
Intracellular cyclic guanosine monophosphate (cGMP), increased by nicorandil, 370, 371
Intravenous metoprolol, during angioplasty in patients with single-vessel coronary artery disease, 677–681
Intraventricular conduction, disorders and arrhythmogenicity of antiarrhythmic drugs, 217–223
Intrinsic sympathomimetic activity (ISA), 114, 304
  epanolol, 125, 129–131, 193, 197, 202
Inward rectifier K^+ channel, lymphosphatidylcholine and palmitoylcarnitine effects on inward rectifier K^+ current, 575–583
Ion channels, 489
I_{to} regulation
  A-type current seen in heart, voltage-gated cloned cardiovascular K^+ channels, 585, 591
  cardiac hypertrophy and enhanced I_{to}, 611–618
Iron overload, in ischemic and reperfused rat heart, 701–710
Ischemia-reperfusion, ventricular fibrillation in hypertrophied rat myocardium by diltiazem, 225–230
Ischemic endpoints, definition of, 276, 279
Ischemic Event Endpoint Committee, 276
Ischemic heart disease, diuretic therapy, 57, 58, 59
Isolated rat heart, iron overload in ischemic and reperfused rat heart, 701–710
Isolated systolic hypertension (ISH), 648
Isoniazid, acetylation, polymorphic, 312–313
Isoprenaline, 113, 304, 305, 306
  effect on rat heart response to adrenergic stimulants after cardioplegic arrest, 851–860
  effect on left ventricular relaxation, 328
Isosorbide dinitrate (ISDN), effect on superior mesenteric artery impedance in humans, 169–174
Isradipine, 722
  adverse reactions, 135, 137
  dose titration study in Chinese patients with essential hypertension, 133–138
  hemodynamic effects in peripheral vascular disease, 556
  hypertension in the elderly, 650

Johns Hopkins Precursors Study, 791
Judkins' technique, 327
Junctional ectopic tachycardia, adenosine able to terminate episodes of, 141–142

K 105, 305
Kaliuresis, 26, 37–38
  hydrochlorothiazide-induced, 32–33
  torasemide effect, 29
Kallikrein, cicletanine effect in men, 253–256
Kane study, 779
Kaplan-Meyer product limit survival analysis, 118
K channel blocker, vs. E-4031, 621–626
K^+ channel openers
  activation of K channels in vascular smooth muscle cells, 539–545
  potassium channels and arterial tone, 605–609
  vs. Ca^{2+} influx and release, 565–572
K channels, 489
  activation of ATP-sensitive K channels by K channel openers in vascular smooth muscle cells, 539–545
  delayed rectifier K current regulation by neurotransmitters and magnesium, 547–553
  glibenclamide failure to inhibit the

opening of ATP-sensitive K channels, 495–497
molecular and functional diversity of cloned cardiac potassium channels, 585–591
review policy for supplement, 493
K^+ current, use-dependent block of the delayed K^+ current in rabbit ventricular myocytes, 599–603
Ketanserin
EADs abolished by pinacidil, 511
effects on serotonin-induced coronary artery spasm in pigs, 268, 269, 270
hemodynamics of long-term antihypertensive therapy, 193–198, 200
Ki4032, vs. Ca^{2+} influx and release, 565–572
Kidney, renal effects of torasemide and furosemide, 11–20
KRN2391, vs. Ca^{2+} influx and release, 565–572
Kruskall-Wallis test, 226, 235

Lactate, metabolism determined enzymatically, 678, 679, 680, 681
Lambeth conventions, 234
diagnostic criteria for ventricular tachycardia (VT) and ventricular fibrillation (VF), 226
Lan-DeMets procedures, 278
Large coronary artery, nicorandil and cromakalim effects, 691–698
Left ventricular dysfunction
ACE inhibitor dosing, 891–892
ACE inhibitors vs. diuretics, 877–879
hypertension in the elderly, 649–650
Left ventricular hypertrophy (LVH)
hypertension in the elderly, 649
reperfusion-induced ventricular fibrillation in rat myocardium by diltiazem, 225–230
Lemakalim (BRL 38227), 561, 572, 597
potassium channels and arterial tone, 605–609
Lidocaine
reducing myocardial damage in experimental models of ischemia, 165
vs. antiarrhythmic drugs, 222
Lifestyle Heart Trial, 769–770
Lipid lowering drugs, as treatment for atherosclerosis, 767–772
Lipid Research Clinics Program trials, 779
Lipid metabolism, diuretics and, 58
Lipoprotein-associated coagulation inhibitor, 829
Lipoprotein associated extrinsic pathway inhibitor (LACI), 820
Lisinopril, hemodynamics of long-term antihypertensive therapy, 193–200
Lithium clearance, xamoterol renal effects, 114
Local cardioplegic effect, by potassium channel activators, 507, 510, 511
Long QT-syndrome, 511

Loop diuretics, 56; *see also* Torasemide
antihypertensive therapy, historical review of, 55–62
antihypertensive treatment, 8
biphasic character of responses of urinary sodium and chloride excretions, 33, 34
and congestive heart failure, 8–9, 40–41
early-afterdosing prokaliuretic effect, 37–38
essential hypertension, 40
extrarenal effects, 19–20
mode of action in chronic renal failure, 75–76
relatively low potency of common formulations, 26
renal effects, 11–20
renal excretory potency, 23, 24–26
time courses of urinary excretions after administration, 38–39
torasemide, 7
urinary excretory responses, 7
vs. others in congestive heart failure treatment after myocardial infarction, 869–875
Loop of Henle, 23, 36, 37, 38
torasemide renal effects, 11–20
Lowry's method, protein determination, 366
LP-805
activation of K channels in vascular smooth muscle cells, 540
chemical structure, 540
Lysophosphatidylcholine, effect on inward rectifier K^+ current, 575–583

McArdle's Syndrome, 748
Magnesium
regulation of cardiac delayed rectifier K current, 547, 551–552, 553
wasting, diuretics and, 58
Manchester/Oxford, Platt/Pickering controversy, 733
MDPIT, with diltiazem, 381–382
Mean segment diameter index (MSDI), 279
Mechanism of anginal pain, adenosine as a pain messenger for angina pectoris, 745–756
Medical Research Council trial, 62
Medical Research Council Trial of Treatment of Hypertension in Older Adults, 648
Membrane potential, potassium channels and arterial tone, 605–609
Membrane stabilizing properties, partial agonists, 303–308
Mephenytoin, oxidation exhibits genetic polymorphism unrelated to sparteine and debrisoquine, 312
Mepindolol, 305
Mesenteric artery, isosorbide dinitrate impedance in humans, 169–174

Meta-analysis, low cholesterol as cause of deaths, 789–893
Metabolic inhibition
ATP-sensitive K^+ channels in the heart, 499–504
glibenclamide failure to inhibit the opening of ATP-sensitive K channels, 495–497
Metabolic side effects
antihypertensive diuretic therapy, 55–62
torasemide vs. thiazides for hypertension, 63–67
Metformin, for treatment of patients with hypertriglyceridemia associated with diabetes or reduced carbohydrate tolerance, 299, 300
Metolazone, 23
for heart failure, 664
Metoprolol, 304, 308
adverse reactions in poor metabolizers, 313
$beta_1$- and $beta_2$-receptor occupancy in plasma, 839–848
coronary venous retroinfusion, 159–166
eliminated via the sparteine/debrisoquine oxygenase, 312
for congestive heart failure, with enoximone, 337–345
genetic polymorphism, 313–314
oxidative metabolism, 313
potential therapeutic implications of poor vs. extensive metabolizer status, 312
vs. nicorandil in stable effort angina pectoris, 119–123
with captopril for congestive heart failure in mice, 795–799
with quinidine, 319
Mexiletine
eliminated via the sparteine/debrisoquine oxygenase, 312
with amiodarone, 684
Mice, metoprolol with captopril for congestive heart failure, 795–799
Microperfusion, evaluation of renal and extrarenal sites of furosemide and torasemide, 11, 17, 18
Micropuncture, evaluation of renal and extrarenal sites of furosemide and torasemide, 11, 17, 19
Microvascular angina pectoris, 746
Milrinone
for heart failure, 665
long-term risks and short-term benefits, 655–659
use in cardiac surgical patients, 671–674
Mineralocorticoids, 16
minK channel protein, 627, 631–634
Minoxidil, activation of K channels in vascular smooth muscle cells, 539–545
Minoxidil sulfate, potassium channels and arterial tone, 605–609

Mivazerol, improvement of exercise tolerance in angina, 929–933
Mortality
  cholesterol confusion in primary prevention of coronary artery disease, 779–783
  low cholesterol as cause of deaths, 789–793
Mortality trials, angiotensin-converting enzyme inhibitor dosing in patients with left ventricular dysfunction, 891–892
MRC Hypertension Trial, 864
Multicenter European Research Trial with Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR), 273
Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS), 771
Multiple Risk Factor Intervention Trial (MRFIT), 57, 780, 785–786
Muzolimine
  clinical and hemodynamic correlates of response, 48, 49, 50
  essential hypertension, 40
  neurotoxic effects, 8
  nondiuretic formulations, 24
  oral administration effects (various doses) on 24-hour urinary sodium output in healthy subjects, 25
  vs. torasemide for hypertension, 66
  withdrawn due to severe neurological side effects in chronic renal failure patients, 79
  withdrawn from market because of nephrotoxicity, 23
Myocardial energetics, enoximone effect alone and with metoprolol, 337–345
Myocardial infarction
  ACE inhibitor dosing in postinfarct protection, 881–882
  amiodarone for malignant ventricular tachyarrhythmias, 683–688
  emergency evaluation and treatment, 283
  loop diuretics vs. others in congestive heart failure after, 869–875
Myocardial ischemia
  action potential duration shortening, 499–504
  aggravation of arrhythmogenicity of antiarrhythmic drugs, 217–223
  ATP-sensitive K^+ channel current role in arrhythmias, 521–524
  ATP-sensitive K^+ channels, protection of the myocardium, 527–536
  definition of term, 507
  E-4031 and tedisamil effects on reperfusion-induced arrhythmias and QT interval in rats, 234, 235–236, 237, 238
  iron overload in ischemic and reperfused rat heart, 701–710
  metoprolol coronary venous retroinfusion effects, 159–166
  modulation by regulation of the ATP-sensitive potassium channel, 507–511
  quinapril evaluation as therapy after coronary artery intervention, 273–280
  trimetazidine (intracoronary) effect on regional function in pigs, 801–807
Myocardial protection (book review), 185
Myogenic tone, potassium channels and arterial tone, 605–609
Myosin light chain, 370

n-3 fatty acids
  influences on hemostasis, 817–822
  to reduce hypertriglyceridemia in a dose-dependent fashion, 298–299, 300
Na, K-ATPase, importance during digitalization of human skeletal muscle digitalis glycoside receptors, 175–180
Naloxone, 752
National Heart and Lung Institute, 779, 780
National Heart, Lung, and Blood Institute (NHLBI), 786
National Heart, Lung, and Blood Institute (NHLBI) Type II Coronary Intervention Study, 768
National Institute of Health (NIH)
  digoxin safety controversy, 898
  NIH Consensus Development Conference on Triglyceride, High Density Lipoprotein, and Coronary Heart Disease, 298
Natriuresis
  cicletanine and prostaglandins, without potassium excretion, 253–256
  fenoldopam intravenous infusion in severe heart failure, 99
  hydrochlorothiazide effects, 29–41
  loop diuretics and, 26, 39, 41
  torasemide ceiling dose, 69
  torasemide effect in patients with advanced renal failure, 75–79
  torasemide induction in cirrhosis and ascites patients, 83
  xamoterol tubular actions overridden by, 114
Nephron ion transport, torasemide effects, 11–20
Nernst equation, 508
Neuman-Logan method, 259
Neural transmission, potassium channel openers' therapeutic potential in peripheral vascular disease and asthma, 555–562
Neurological status, torasemide in patients with chronic renal failure, 79
Neuropeptide-Y, Raynaud's patient sympathetic activation after nifedipine treatment, 901–906
Nicardipine
  inhibiting new lesion progression in coronary artery disease, 273, 280
  plus propranolol, influence on the pharmacokinetics in rats, 721–725
Nicorandil
  activation of K channels in vascular smooth muscle cells, 539–545
  chemical structure, 540
  drug-induced $I_{K,ATP}$ activation, 593–597
  effect on cell proliferation and cholesteryl ester accumulation, 365–371
  effects on the coronary artery, 691–698
  equal in efficacy to propranolol in treatment of angina pectoris, 121
  role in ischemia, 510, 511
  vs. Ca^{2+} influx and release, 565–572
  vs. metoprolol in stable effort angina pectoris, 119–123
Nicotine, adenosine-provoked pain and, 754–755
Nicotinic acid, for treatment of hypertriglyceridemia, 297, 299–300
Nifedipine
  calcium antagonizing action, 262
  genetic polymorphism, 321
  hypertension in the elderly, 650
  improvement of hemodynamics of patients with heart failure, 103, 107, 108
  inducing diuresis and natriuresis, 255
  inhibiting new lesion progression in coronary artery disease, 273
  negative inotropic effect in congestive heart failure patients, 93–94
  no improvement in acute myocardial infarction patients without heart failure, 117–118
  oxidation exhibiting genetic polymorphism unrelated to sparteine and debrisoquine, 312
  plus propranolol, influence on the pharmacokinetics in rats, 721–725
  protective effect on rat hearts during cardioplegic arrest, 851–860
  Raynaud's patient sympathetic activation after treatment with, 901–906
  slow-release, vs. (and combined with) atenolol in stable angina, 909–913
  vs. CD-832 for coronary artery spasm in pigs, 265–270
  with propranolol, 315
  with trimetazidine, 155
Nimodipine, potassium channels and arterial tone, 607
Nisoldipine
  effects on hemodynamics, neurohumoral parameters, and functional capacity with chronic heart failure, 103–108
  for congestive heart failure patients, 93–94
  hypertension in the elderly, 650

Nitrates
isosorbide dinitrate influence on superior mesenteric artery impedance in humans, 169–174
nicorandil's hybrid property between potassium channel openers and, 691–698
Nitrendipine, hemodynamic effects in peripheral vascular disease, 556, 558, 559
Nitroglycerin, 266, 698
and adenosine, 752, 754
consumption reduced by nicorandil and metoprolol, 121
relaxant effects of nicorandil or KRN2391 similar, 567, 571
Nitroprusside, hemodynamic response in dogs with chronic heart failure, 349–355
Nitrovasodilators, 370
Non-adrenergic non-cholinergic (NANC) transmission, airway hyperactivity inhibition with potassium channel openers, 555–562
Noradrenaline, 698
Raynaud's patient sympathetic activation after nifedipine treatment, 901–906
Norwegian State Drug Control, 194
epanolol vs. atenolol study protocol approved, 126
N-propylajmaline (NPAB)
eliminated via the sparteine/debrisoquine oxygenase, 312
genetic polymorphism, 319–320
Nuclear magnetic resonance (NMR) spectroscopy
propionyl-L-carnitine effect on rats, 241, 243, 249–250
used to show recovery of leg muscle phosphocreatine levels in patients with intermittent claudication, 556–557
Nucleoside, adenosine therapeutic and diagnostic cardiac electrophysiological uses, 139–145
Nucleotides, activation of ATP-sensitive K channels by K channel openers in vascular smooth muscle cells, 545

Open channel block, use-dependent block of the delayed K^+ current in rabbit ventricular myocytes, 599–603
Oxidized lipoproteins, blood lipid lowering as treatment for atherosclerosis, 767–772
Oxprenolol, 304, 305
Oxygen free radicals
promoted by iron overload effect in ischemic and reperfused rat heart, 701, 702, 705–706, 708, 709
trimetazidine (intracoronary) effect on regional function of repeated ischemia in pigs, 801, 806–807
Ozolinone, 23

P-450, genetic influences on cardiovascular drug metabolism, 311–321
P450IID6, 312
P450IIIA4 isozyme, 321
Pain, scoring with Borg's new pain scale during coronary angioplasty, 678, 679
Palmitate, with propionyl-L-carnitine, dependent effect on energy in hypertrophied rat hearts, 357–362
Palmitoylcarnitine, effect on inward rectifier K^+ current, 575–583
Partial agonism (PA)
assessment of, 304–305
of beta-blockers, 303–308
Patch clamp techniques
delayed K^+ current in guinea pig sinoatrial node, 627–634
delayed rectifier K current regulation by neurotransmitters and magnesium, 547–553
investigation of lymphosphatidylcholine and palmitoylcarnitine effects on inward rectifier K^+ current, 575–583
PDE inhibitors, for heart failure, 665
Pelninone, 656
Penbutolol, 305
Pentoxifylline, vs. propionyl-L-carnitine, 242, 246
Percutaneous gene therapy, 285
Percutaneous transluminal coronary angioplasty (PTCA)
adenosine effect, 753–754
metoprolol intravenously given to patients with single-vessel coronary artery disease, 677–681
propranolol regional beta-blockade, 166
trimetazidine effect on recovery of regional function in pigs, 801–807
Perhexiline
eliminated via the sparteine/debrisoquine oxygenase, 312
genetic polymorphism, 320–321
pharmacologic response, 321
potential therapeutic implications of poor vs. extensive metabolizer status, 312
Peripheral vascular disease, potassium channel openers' therapeutic potential, 555–562
Peripheral vascular resistance, increase in elderly due to hypertension, 643–650
Pfeffer study, 795
$PGF_{2\alpha}$, 691, 693, 694, 697
Pharmacodynamics, torasemide, 69–73
Pharmacokinetics
calcium antagonist influence on the pharmacokinetics of propranolol in rats, 721–725
slow-release verapamil antihypertensive effect, 899–900
torasemide, 69–73
Phenocopying, 318
Phenylephrine, 693, 694, 697, 698
Phenytoin, acetylation, polymorphic, 313
Phosphodiesterase III inhibitors
long-term risks and short-term benefits, 655–659
milrinone use in cardiac surgical patients, 671–674
Physiology, cardiac (book review), 287
Pigs
arrhythmogenicity of antiarrhythmic drugs, 217–223
CD-832 effect on coronary artery spasm, 265–270
metoprolol coronary venous retroinfusion, 159–166
nicorandil's and cromakalim's effects on the large coronary artery, 691–698
Pimobendan, 656
Pinacidil
activation of K channels in vascular smooth muscle cells, 539–545
chemical structure, 540
drug-induced $I_{K,ATP}$ activation, 593–597
increasing incidence of ventricular fibrillation with onset of ischemia, 522, 523
potassium channels and arterial tone, 605–609
role in ischemia, 510–511
to activate varied ischemic injury and cause decline in action potential duration, ATP-sensitive K^+ channels, 527–536
vs. Ca^{2+} influx and release, 565–572
Pindolol, 304, 305, 306, 307, 308
$beta_1$- and $beta_2$-receptor occupancy in plasma, 839–848
beta blockade and lowering of TPRI below pretreatment level during chronic treatment, 130
Piretanide, 23, 24
acute hemodynamic actions, 46, 47, 48
oral administration effects (various doses) on 24-hour urinary sodium output in healthy subjects, 25
Piroximone, long-term risks and short-term benefits, 656–659
Plasma renin activity (PRA), increase with diuretic therapy, 45–46
Platelet aggregation, trimetazidine effect causing decline in coronary artery blood flow, 153, 155
Polymodal receptors, 748
Population, treatment of mild hypercholesterolemia in the absence of overt cardiovascular disease, 775–776
Post myocardial infarction
digoxin safety, 893–895
diuretics in postinfarction heart failure, 885–888
Potassium
flow dependence of distal potassium secretion, 14–15, 16, 17–18
loss because of ischemia, thus promoting early arrhythmias, 507–508

urinary excretion after hydrochlorothiazide dose, 32–33
urinary excretion after torasemide dose, 37–38
Potassium accumulation, ATP-sensitive K^+ channels and their metabolic regulation, 499–504
Potassium canrenoate, 23, 81
Potassium channel activators, modulation of ischemia, 507–511
Potassium channel blockade, E-4031 and tedisamil effects on reperfusion-induced arrhythmias and QT interval in rats, 233–239
Potassium channel openers
ATP-sensitive K^+ channel current role in ischemic arrhythmias, 521–524
cromakalim effect on the coronary artery, 691–698
drug-induced $I_{K,ATP}$ activation, 593–597
nicorandil's hybrid property between nitrates and, 691–698
therapeutic potential in peripheral vascular disease and asthma, 555–562
Potassium excretion
in cirrhosis and ascites patients given torasemide, 84
xamoterol renal effects on congestive heart failure, 112
Potassium loss, ATP-sensitive K^+ channels and their metabolic regulation during ischemia and hypoxia, 499–504
Potassium transport along the nephron, 13–14
Potassium-retaining diuretics, vs. loop diuretics in congestive heart failure after myocardial infarction, 869–875
Practolol, 304, 305, 307
Pravastatin, effect on hemostasis, 818
Pravastatin, Lipids and Atherosclerosis in the Carotids study (PLAC-2), 771
Prazosin, vs. doxazosin, 198
Preexcitation, unmasked by adenosine's transient blockade of trioventricular node, 139, 143–144, 145
Prenalterol, 304, 305, 307
Prenylamine, 183
Primary prevention, cholesterol confusion, for coronary artery disease, 779–783
Prinzmetal's variant angina, 265
Proarrhythmic effect, antiarrhythmic drugs flecainide, propafenone, and cibenzoline, 222
Probability, assurance against drug-induced death in heart failure patients, 829–830
Probenecid, with torasemide, 18
Probucol, effect on hemostasis, 821–822
Procainamide
acetylation, polymorphic, 312–313
genetic polymorphism, 320
pharmacologic response, 321
with amiodarone, 684
Prognosis, diuretics in postinfarction heart failure, 885–888
Program on the Surgical Control of the Hyperlipidemias (POSCH), 769, 779
Propafenone, 311
adverse reactions in poor metabolizers, 313
arrhythmogenicity and intraventricular conduction disorders, 217, 219, 220, 222, 223
eliminated via the sparteine/debrisoquine oxygenase, 312
genetic polymorphism, 317–318
pharmacologic response, 321
potential therapeutic implications of poor vs. extensive metabolizer status, 312
with amiodarone, 684
with metoprolol, 314
Propionylcarnitine, preventing the depressant effect of lysophosphatidylcholine but not of palmitoylcarnitine, 575, 581, 582, 583
Propionyl-D-carnitine (PDC), vs. propionyl-L-carnitine, 243
Propionyl-L-carnitine (PLC)
effect on hypertrophied rat hearts, 357–362
in experimental arteriopathy in rats, 241–251
vs. pentoxifylline, 242, 246
vs. propionyl-D-carnitine, 243
Propranolol, 306, 307, 308
adverse reactions in poor metabolizers, 313
$beta_1$- and $beta_2$-receptor occupancy in plasma, 839–848
development of, 303–304
drawbacks, 303
eliminated via the sparteine/debrisoquine oxygenase, 312
equal in efficacy to nicorandil in treatment of angina pectoris, 121
genetic polymorphism, 315
infarct size reduction inversely related to delay in drug administration during ischemia in dogs, 165
oxidative metabolism, 313
protective effect on rat hearts during cardioplegic arrest, 851–860
vs. E-4031, 622–626
vs. epanolol, hemodynamic effects, 130
with calcium antagonists, influence on pharmacokinetics in rats, 721–725
Prospective Randomized Amlodipine Survival Evaluation (PRAISE), 95, 284
Prostacyclin, cicletanine effect in men, 253–256
Protection, ACE inhibitor dosing in postinfarct protection, 881–882
PROVED study, 284
Proximal tubule, sodium reabsorption with xamoterol, 113
Pseudo-resistant hypertension, 8
Pulsatility index, of superior mesenteric artery, isosorbide dinitrate influence, 169–174

QT interval
E-4031 effect in rats in vivo, 233–239
tedisamil effect in rats in vivo, 233–239
QUinapril Ischemic Event Trial (QUIET), 273–280
Quinidine
drug interactions, 319
genetic polymorphism, 319
interaction with adenosine, 145
pharmacologic response, 321
potential therapeutic implications of poor vs. extensive metabolizer status, 312
use-dependent block of the delayed K^+ current in rabbit ventricular myocytes, 599–603
vs. antiarrhythmic drugs, 222
with ajmaline, 319
with encainide, 319
with metoprolol, 319

Rabbits
cardiac ATP-sensitive K^+ channels, 499–504
clentiazem inhibitory effect on balloon catheter-induced intimal thickening of aorta, 257–263
potassium channel openers' therapeutic potential in peripheral vascular disease and asthma, 555–562
use-dependent block of the delayed K^+ current in ventricular myocytes, 599–603
RADIANCE study, 284
Randall Selitto test, 250
Rate-pressure product, metoprolol influence during coronary angioplasty, 678, 679
Rats
beta-blocker and Ca^{2+} antagonist effects on heart response to adrenergic stimulants after cardioplegic arrest, 851–860
calcium antagonist influences on the pharmacokinetics of propranolol, 721–725
diltiazem and hypertrophied myocardium, 225–230
glibenclamide failure to inhibit the opening of ATP-sensitive K channels, 495–497
iron overload effect in the isolated ischemic and reperfused heart, 701–710
nicorandil effects on cell proliferation and cholesterol ester accumulation in arterial smooth muscle cells, 365–371
potassium channel openers' therapeutic potential in peripheral vascular disease and asthma, 556–557, 558, 559

propionyl-L-carnitine effect on hypertrophied hearts, 357–362
propionyl-L-carnitine effect on peripheral arteriopathy, 241–251
Raynaud's disease, partial agonists and, 310n
Raynaud's phenomenon, sympathetic activation after nifedipine treatment, 901–906
Recombinant single-chain urokinase-type plasminogen activator (rscu-PA), 825–826
Recombinant tissue-type plasminogen activator (rt-PA), 825–826
Reentry, E-4031 effect on reentrant ventricular arrhythmias, 621–626
Regional Ethical Committee, 194
Regional myocardial perfusion and function, trimetazidine (intracoronary) effect, repeated ischemia in pigs, 801–807
"Regression to the mean" phenomenon, 817
Relaxation phase, dobutamine and ventricular relaxation, 325–329
Remodeling, ACE inhibitor dosing in postinfarct protection, 881–882
Renal clearance, torasemide and furosemide, 15–20
Renal function
cicletanine effect in men, 253–256
xamoterol effects, 111–115
Renal insufficiency
torasemide pharmacodynamics, 69–73
torasemide pharmacokinetics, 69–73
Reocclusion, prevention by defibrotide vs. heparin after thrombolysis in acute myocardial infarction, 809–814
Reperfusion
E-4031 and tedisamil effects on reperfusion-induced arrhythmias and QT interval in rats, 233–239
iron overload in ischemic and reperfused rat heart, 701–710
metoprolol coronary venous retroinfusion after, 159–166
pathophysiology of, and myocardial protection, 185
trimetazidine (intracoronary) effect, repeated ischemia in pigs, 801–807
Reperfusion arrhythmias, diltiazem effect on hypertrophied rat myocardium, 225–230
Reperfusion injury, pathophysiology of, and myocardial protection, 185
Respiration in dog, hydrogen peroxide reducing arterial pressure and respiration in the anesthetized dog, 731–732
Respiratory work, loop diuretics vs. others in congestive heart failure treatment after myocardial infarction, 869–875
Reverse autoregulation, 45
Reverse use dependence, 603
Right ventricular function, milrinone effects, 673–674
Right ventricular hypertrophy, and enhanced I_{to}, 611–618
Risotilide, 233
RO 13-6438, 656
RP 49356, potassium channels and arterial tone, 605–609
Rundown, 593, 595–596, 597

Safety Data Monitoring Committee, 277–278
St. Thomas' Atherosclerosis Regression Study (STARS), 770, 779
SAN cells, 627–634
SAS LIFETEST procedure, 118
Schiff base, 593, 595, 597
Screening, for hypertensive employees on worksite, 207
SDZ PCO-400, airway hyperactivity inhibited by potassium channel openers, 555–562
Secondary prevention, cholesterol confusion and trials, 779–783
Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) study, 117, 118, 381
Serotonin, 265–270
hemodynamics of long-term antihypertensive therapy, 200, 201
Serum lipids, modification to prevent coronary heart disease, 761–764
Sick sinus syndrome, 630
Silent ischemia, adenosine as a pain messenger, 745–756
Simvastatin, 213
effect on hemostasis, 820
Single channel recording, ATP-sensitive K^+ channel dependent gating, 515, 516, 518
Sinoatrial node, delayed K^+ current in guinea pigs, 627–634
Skeletal muscle, digitalis glycoside receptors (Na, K-ATPase) importance during digitalization, 175–180
Slow-release nifedipine, vs. (and combined with) atenolol in stable angina, 909–913
Smoking
and hypercholesterolemia, 775–776
hypertension in the elderly, 648
Smooth muscle cell proliferation, prevented by clentiazem in atheromatous lesions, 257–263
Sodium channel blockers, arrhythmogenicity of antiarrhythmic drugs and intraventricular conduction disorders, 217–223
Sodium excretion
fenoldopam intravenous infusion in severe heart failure, 99
in cirrhosis and ascites patients given torasemide, 83, 84
xamoterol renal effects on congestive heart failure, 112, 113, 114
Sodium restriction
hemodynamics of long-term antihypertensive therapy, 193–198, 202
hypertension in the elderly, 646
Sodium transport, along the nephron, 11–20
Sotalol, 237–238, 306
use-dependent block of the delayed K^+ current in rabbit ventricular myocytes, 599–603
Sparteine, eliminated via the sparteine/debrisoquine oxygenase, 312
Specialized Center of Research (SCOR) Intervention Trial, 769, 770
Specific digoxin F_{ab}, digitalis glycoside receptors binding by, digoxin reduced by, 177, 178
Spironolactone, 23, 81, 875
as facultative diuretic, 24
oral administration effects (various doses) on 24-hour urinary sodium output in healthy subjects, 25
Splanchnic circulation, isosorbide dinitrate influence on the superior mesenteric artery in humans, 169–174
Staphylokinase, 826
Starling's curve, 9, 41
Staurosporine, effect on I_{to} in normal RV myocytes, 616–617
ST elevation, amlodipine besilate evaluation by 24-hour Holter monitoring for variant angina, 923–928
Stockholm Heart Study (SHS), 771
Stockholm Ischemic Heart Disease Study, nicotinic acid and clofibrate tested for coronary heart disease, 297
STOP trial, 648
Streptokinase, 825–826
Stretch
flecainide acetate electrophysiological effects on guinea-pig left atrial muscle, 373–378
role played in pathogenesis of atrial arrhythmias, 377
Student's paired t-test (changes in developed tension), 226
Studies Of Left Ventricular Dysfunction (SOLVD), 273–274, 283, 795, 863, 865, 881
Sudden death
amiodarone and prognosis after myocardial infarction, 683–688
arrhythmogenicity of antiarrhythmic drugs and intraventricular conduction disorders, 217
definition of, 276
myocardial hypertrophy and enhanced I_{to}, 611
verapamil as preventative measure in patients with increased heart size after acute myocardial infarction, 381–382

Sulfasalazine, 312–313
Sulfonylureas
  antiarrhythmic effect in initial phase of ischemia, 522, 523, 524
  inhibiting early ischemic arrhythmias, 536
  potassium channels and arterial tone, 605–609
Sulmazole, 656
Supplements
  gold standard, 491
  origin and significance, a response to the *New England Journal of Medicine*, 491–492
Supraventricular tachycardia, adenosine's ability to distinguish from ventricular tachycardia, 139, 140–141, 142–143, 145
Survival And Ventricular Enlargement Trial (SAVE), 274, 863, 865, 881–882
Swedish Trial in Old Patients with Hypertension (STOP-Hypertension), 62
Sympathetic activity, hypertensive labeling, 207–209
Sympathicolytics, 59
Syndrome X, 283, 818, 821
  sensitivity to adenosine-provoked pain, 745, 746, 747, 752, 754
Systemic lupus erythematosus (SLE), 320
  hydralazine as cause, 321
Systolic Hypertension in the Elderly Program (SHEP), 61, 62, 648

TA-3090. *See* Clentiazem
Tedisamil
  effect on reperfusion arrhythmias and QT interval in rats, 233–239
  use-dependent block of the delayed K^+ current in rabbit ventricular myocytes, 599–603
  with E-4031, 236–239
Tetrabutylammonium (TBA), 565, 567, 571, 572
Tetraethylammonium (TEA), 567, 571, 587, 632
  potassium channels and arterial tone, 605–609
TF-VII monoclonal antibody, 827
Theophylline, 751, 753, 754
Therapeutic considerations, hypertension in the elderly, 643–650
Therapeutic paradox of beta-blockade, 125
Thiazides, 15, 23, 59
  diuretic therapy for hypertension, historical review, 55–62
  effect on urinary calcium, 33
  vs. torasemide for hypertension, 63–67
Thrombin, thrombolytic therapy and anticoagulants, 825–827
Thrombocytopenia, in severe heart failure patients with fenoldopam intravenous infusion, 97, 100
Thrombolysis, defibrotide vs. heparin to prevent coronary reocclusion after thrombolysis in acute myocardial infarction, 809–814
Thrombolytics, agents of therapy and anticoagulants, 825–827
Thrombosis, lipid-modifying agent influences on hemostasis, 817–822
Thromboxane, urinary excretion and the cicletanine effect in managing cardiovascular disorders, 253–256
Thromboxane A_2 analogue. *See* U 46619
Thrombus formation, index of, 154–155
Tick anticoagulant peptide, 827
Tienilic acid, 23
TIMI IIIB trial, unstable angina, 284
Timolol
  adverse reactions in poor metabolizers, 313
  eliminated via the sparteine/debrisoquine oxygenase, 312
  genetic polymorphism, 314–315
  oxidative metabolism, 313
Tissue factor pathway inhibitor (TFPI), 820
Tizolemide, 23, 24
  oral administration effects (various doses) on 24-hour urinary sodium output in healthy subjects, 25
Tolbutamide, 495
  antiarrhythmic effect, 524
  blocking hyperpolarizations and dilations, 607–608
  oxidation exhibiting genetic polymorphism unrelated to sparteine and debrisoquine, 312
  reducing ischemic arrhythmias in perfused rat or rabbit hearts, 536
TOMH study, 783
Tonic blockade, 600
Torasemide, 23, 24, 26
  acute hemodynamic actions, 47, 48
  ceiling dose, 69, 73
  diuretic therapy with, 7–9
  early-afterdosing prokaliuretic effect, 37–38
  effect on renal excretory responses (urinary calcium, sodium, and chloride), 29, 33–41
  effects of oral formulation, 7
  essential hypertension, 40
  furosemide-type substance, 7
  glucose intolerance and, 58
  hypotensive action, 56, 59
  in cirrhosis and ascites patients, 81–84
  loop diuretics vs. others in congestive heart failure treatment after myocardial infarction, 869–875
  nondiuretic formulations, 24
  oral administration effects (various doses) on 24-hour urinary sodium output in healthy subjects, 25
  oral dose exerting natriuretic and diuretic action equivalent to 40 mg. furosemide, 7
  pharmacodynamics in patients with chronic renal insufficiency, 69–73
  pharmacokinetics, in patients with chronic renal insufficiency, 69–73
  renal effects, 11–20
  tubule site of action, 17–19
  vs. bumetanide, 72
  vs. furosemide, 72
  vs. furosemide, in chronic renal failure patients, 75–79
  vs. thiazides for hypertension, 63–67
Transient outward current, cardiac hypertrophy and enhanced I_{to}, 611–618
Treatment, cholesterol lowering for prevention of coronary heart disease, 785–788
Treatment benefits, serum lipid modification to prevent coronary heart disease, 761–764
Treatment risks, serum lipid modification to prevent coronary heart disease, 761–764
Trends in cardiac medicine, 283–285
Triamterene, 23, 875
  with hydrochlorothiazide, vs. torasemide for hypertension, 65, 66, 67
Trimazosin, vs. doxazosin, 198
Trimetazidine
  effect on recovery of regional function in porcine model of repeated ischemia, 801–807
  effects on in vivo coronary arterial platelet thrombosis, 149–156
  with a beta-adrenergic blocking agent or nifedipine, 155
Trypsin (TRYP), 633–634
  effect on $I_{K.ATP}$, 595–596, 597
Tukey's test for multiple comparisons, 226
Two-chain urokinase-type plasminogen activator (tcu-PA), 825–826

U 46619 (Thromboxane A_2 analogue)
  effects of K^+ channel openers on Ca^{2+} influx, 567–571, 572
  to contract cromakalim, 691–698
UK-66, 914, 237, 239
UK-68, 798, 233
Ultrasound
  hypercholesterolemia detection and treatment, 775–776
  noninvasive evaluation of atheroma, 770–771
U.S. National Cholesterol Education Program, Adult Treatment Panel II guidelines, 793
U.S. National Health and Nutrition Surveys (NHANES) Epidemiologic Follow-up Study, 789
University Group Diabetes Program (UGDP), 523–524

Unstable angina pectoris
heparin effect, 284
TIMI IIIB trial, 284
Untreated hypertensives, cardiac output reduced, and congestive heart failure resulting, 193–197, 200
Urate, detection of release during coronary angioplasty, 678, 680
Urinary calcium, hydrochlorothiazide causing reduction, 29–41
Urinary chloride, hydrochlorothiazide causing an increase, 29–41
Urinary potassium, hydrochlorothiazide causing an increase, 29–41
Urinary sodium, hydrochlorothiazide causing an increase, 29, 33–41
Use dependence, 603
Use-dependent block, of delayed K^+ current in rabbit ventricular myocytes, 599–603

Valsalva maneuver, 140
Valvular heart disease, diuretic therapy and acute hemodynamic actions, 46
Vampire bat salivary plasminogen activator (BAT-PA), 826
Variant angina, amlodipine besilate evaluation by 24-hour Holter monitoring, 923–928
Vascular cell, activation of K channel openers in vascular smooth muscle cells, 539–545
Vascular tone, blood lipid lowering as treatment for atherosclerosis, 767–772
Vasoactive intestinal peptide, potassium channels and arterial tone, 605–609
Vasodilation, potassium channels and arterial tone, 605–609
Vasodilator effects, phosphodiesterase III inhibitor risks and benefits, 655–659
Vasodilator therapy
for heart failure, 665–666
discontinued before fenoldopam intravenous infusion in severe heart failure, 97–101
Vasopressin, 37
VeHFT studies, 283
Ventricular fibrillation
amiodarone after myocardial infarction, 683–688
E-4031 and tedisamil effects on reperfusion-induced arrhythmias and QT interval in rats, 233–235, 237, 239
reperfusion-induced and attenuated in the hypertrophied rat myocardium by diltiazem, 225–230
Ventricular tachycardia
amiodarone after myocardial infarction, 683–688
E-4031 effect on reentrant ventricular arrhythmias, 621–626
Verapamil
benefit limited to patients free of congestive heart failure, 117
effect on Ca^{2+} influx, 568, 570
hypertension in the elderly, 650
inhibiting cell proliferation in rat hearts, 366–369
interaction with adenosine, 145
sustained release, antihypertensive effect, 899–900
to prevent sudden death in patients with increased heart size after an acute myocardial infarction, 381–382
vs. adenosine, 145
Vesnarinone (OPC-9121), 656
Veterans Affairs Heart Failure Trial (V-HeFTIII), 95, 284
V-HeFTII trial, 795
Volume factor, 8

Warfarin, 666
White-coat hypertension, 729
hypertensive labeling, 727–728
Whole-cell voltage clamp technique
cardiac hypertrophy and I_{to}, 611–618
for voltage and current-clamp recordings, ATP-sensitive K^+ channel role in action potential shortening and myocardial ischemic protection, 531–532, 533–536
Wilcoxon-Mann-Whitney test (arrhythmia median duration), 226
Wilcoxon's matched-pairs signed-ranks test, 171
Wolff-Parkinson-White syndrome
adenosine's atrioventricular reentry tachycardia involving accessory pathway, 139, 141, 143–144, 145
related tachycardia and flecainide acetate effect, 373
Wolinsky-Daly method, 258
Women
cholesterol lowering for prevention of coronary heart disease, 785–788
coronary artery disease, 283
hypertension as a disease or as a state of doctors' minds, 733–734
serum lipid modification benefits and risks, 761–764
World Health Organization, primary-prevention clofibrate study, 791

Xamoterol, 304, 305, 307
for heart failure, 665
renal effects in patients with congestive heart failure, 111–115
Xipamide, 23, 24
oral administration effects (various doses) on 24-hour urinary sodium output in healthy subjects, 25

Y-26763, 542, 544
chemical structure, 540